00009399302025Q2false--03-31http://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#CostOfGoodsAndServicesSoldhttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#AccruedLiabilitiesCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#OtherAssetsCurrenthttp://fasb.org/us-gaap/2024#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2024#LongTermDebtNoncurrenthttp://fasb.org/us-gaap/2024#LongTermDebtNoncurrentxbrli:sharesiso4217:USDiso4217:USDxbrli:sharesxbrli:purepyx:account00009399302024-04-012024-09-3000009399302024-10-3100009399302024-07-012024-09-3000009399302023-07-012023-09-3000009399302023-04-012023-09-3000009399302024-09-3000009399302023-09-3000009399302024-03-310000939930us-gaap:CommonStockMember2024-03-310000939930us-gaap:RetainedEarningsMember2024-03-310000939930us-gaap:AccumulatedTranslationAdjustmentMember2024-03-310000939930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-03-310000939930us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-03-310000939930us-gaap:NoncontrollingInterestMember2024-03-310000939930us-gaap:RetainedEarningsMember2024-04-012024-06-300000939930us-gaap:NoncontrollingInterestMember2024-04-012024-06-3000009399302024-04-012024-06-300000939930us-gaap:CommonStockMember2024-04-012024-06-300000939930us-gaap:AccumulatedTranslationAdjustmentMember2024-04-012024-06-300000939930us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-04-012024-06-300000939930us-gaap:CommonStockMember2024-06-300000939930us-gaap:RetainedEarningsMember2024-06-300000939930us-gaap:AccumulatedTranslationAdjustmentMember2024-06-300000939930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-06-300000939930us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-06-300000939930us-gaap:NoncontrollingInterestMember2024-06-3000009399302024-06-300000939930us-gaap:RetainedEarningsMember2024-07-012024-09-300000939930us-gaap:NoncontrollingInterestMember2024-07-012024-09-300000939930us-gaap:CommonStockMember2024-07-012024-09-300000939930us-gaap:AccumulatedTranslationAdjustmentMember2024-07-012024-09-300000939930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-07-012024-09-300000939930us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-07-012024-09-300000939930us-gaap:CommonStockMember2024-09-300000939930us-gaap:RetainedEarningsMember2024-09-300000939930us-gaap:AccumulatedTranslationAdjustmentMember2024-09-300000939930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2024-09-300000939930us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2024-09-300000939930us-gaap:NoncontrollingInterestMember2024-09-300000939930us-gaap:CommonStockMember2023-03-310000939930us-gaap:RetainedEarningsMember2023-03-310000939930us-gaap:AccumulatedTranslationAdjustmentMember2023-03-310000939930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-03-310000939930us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-03-310000939930us-gaap:NoncontrollingInterestMember2023-03-3100009399302023-03-310000939930us-gaap:RetainedEarningsMember2023-04-012023-06-300000939930us-gaap:NoncontrollingInterestMember2023-04-012023-06-3000009399302023-04-012023-06-300000939930us-gaap:AccumulatedTranslationAdjustmentMember2023-04-012023-06-300000939930us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-04-012023-06-300000939930us-gaap:CommonStockMember2023-06-300000939930us-gaap:RetainedEarningsMember2023-06-300000939930us-gaap:AccumulatedTranslationAdjustmentMember2023-06-300000939930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-06-300000939930us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-06-300000939930us-gaap:NoncontrollingInterestMember2023-06-3000009399302023-06-300000939930us-gaap:RetainedEarningsMember2023-07-012023-09-300000939930us-gaap:NoncontrollingInterestMember2023-07-012023-09-300000939930us-gaap:AccumulatedTranslationAdjustmentMember2023-07-012023-09-300000939930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-07-012023-09-300000939930us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-07-012023-09-300000939930us-gaap:CommonStockMember2023-09-300000939930us-gaap:RetainedEarningsMember2023-09-300000939930us-gaap:AccumulatedTranslationAdjustmentMember2023-09-300000939930us-gaap:AccumulatedDefinedBenefitPlansAdjustmentMember2023-09-300000939930us-gaap:AccumulatedGainLossNetCashFlowHedgeParentMember2023-09-300000939930us-gaap:NoncontrollingInterestMember2023-09-300000939930us-gaap:ProductMemberpyx:LeafTobaccoNorthAmericaSegmentMember2024-07-012024-09-300000939930us-gaap:ProductMemberpyx:LeafTobaccoNorthAmericaSegmentMember2023-07-012023-09-300000939930us-gaap:ProductMemberpyx:LeafTobaccoNorthAmericaSegmentMember2024-04-012024-09-300000939930us-gaap:ProductMemberpyx:LeafTobaccoNorthAmericaSegmentMember2023-04-012023-09-300000939930us-gaap:ServiceMemberpyx:LeafTobaccoNorthAmericaSegmentMember2024-07-012024-09-300000939930us-gaap:ServiceMemberpyx:LeafTobaccoNorthAmericaSegmentMember2023-07-012023-09-300000939930us-gaap:ServiceMemberpyx:LeafTobaccoNorthAmericaSegmentMember2024-04-012024-09-300000939930us-gaap:ServiceMemberpyx:LeafTobaccoNorthAmericaSegmentMember2023-04-012023-09-300000939930pyx:LeafTobaccoNorthAmericaSegmentMember2024-07-012024-09-300000939930pyx:LeafTobaccoNorthAmericaSegmentMember2023-07-012023-09-300000939930pyx:LeafTobaccoNorthAmericaSegmentMember2024-04-012024-09-300000939930pyx:LeafTobaccoNorthAmericaSegmentMember2023-04-012023-09-300000939930pyx:OtherProductsAndServicesSegmentMember2024-07-012024-09-300000939930pyx:OtherProductsAndServicesSegmentMember2023-07-012023-09-300000939930pyx:OtherProductsAndServicesSegmentMember2024-04-012024-09-300000939930pyx:OtherProductsAndServicesSegmentMember2023-04-012023-09-300000939930us-gaap:RestrictedStockUnitsRSUMember2024-07-012024-09-300000939930us-gaap:RestrictedStockUnitsRSUMember2024-04-012024-09-300000939930pyx:AdamsInternationalLtdMember2024-09-300000939930pyx:AllianceOneIndustriesIndiaPrivateLtdMember2024-09-300000939930pyx:ChinaBrasilTabacosExportadoraS.A.Member2024-09-300000939930pyx:OryantalTutunPaketlemeMember2024-09-300000939930pyx:PurilumLLCMember2024-09-300000939930pyx:SiamTobaccoExportCorporationLtdMember2024-09-300000939930us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-07-012024-09-300000939930us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-07-012023-09-300000939930us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-04-012024-09-300000939930us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-04-012023-09-300000939930us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-09-300000939930us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2023-09-300000939930us-gaap:EquityMethodInvestmentNonconsolidatedInvesteeOrGroupOfInvesteesMember2024-03-310000939930us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-09-300000939930us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2023-09-300000939930us-gaap:VariableInterestEntityNotPrimaryBeneficiaryMember2024-03-310000939930us-gaap:CustomerRelationshipsMember2024-09-300000939930us-gaap:TechnologyBasedIntangibleAssetsMember2024-09-300000939930us-gaap:TradeNamesMember2024-09-300000939930us-gaap:CustomerRelationshipsMember2023-09-300000939930us-gaap:TechnologyBasedIntangibleAssetsMember2023-09-300000939930us-gaap:TradeNamesMember2023-09-300000939930us-gaap:CustomerRelationshipsMember2024-03-310000939930us-gaap:TechnologyBasedIntangibleAssetsMember2024-03-310000939930us-gaap:TradeNamesMember2024-03-310000939930pyx:ABLFacilityMemberus-gaap:LineOfCreditMember2024-09-300000939930pyx:ABLFacilityMemberus-gaap:LineOfCreditMember2023-09-300000939930pyx:ABLFacilityMemberus-gaap:LineOfCreditMember2024-03-310000939930pyx:SeniorSecuredFirstLienNotesDue2024Memberus-gaap:SeniorNotesMember2024-09-300000939930pyx:SeniorSecuredFirstLienNotesDue2024Memberus-gaap:SeniorNotesMember2023-09-300000939930pyx:SeniorSecuredFirstLienNotesDue2024Memberus-gaap:SeniorNotesMember2024-03-310000939930pyx:SeniorSecuredFirstLienNotesDue2027Memberus-gaap:SeniorNotesMember2024-09-300000939930pyx:SeniorSecuredFirstLienNotesDue2027Memberus-gaap:SeniorNotesMember2023-09-300000939930pyx:SeniorSecuredFirstLienNotesDue2027Memberus-gaap:SeniorNotesMember2024-03-310000939930pyx:IntabexTermLoanMember2024-09-300000939930pyx:IntabexTermLoanMember2023-09-300000939930pyx:IntabexTermLoanMember2024-03-310000939930pyx:PyxusTermLoanMember2024-09-300000939930pyx:PyxusTermLoanMember2023-09-300000939930pyx:PyxusTermLoanMember2024-03-310000939930pyx:OtherLongTermDebtMember2024-09-300000939930pyx:OtherLongTermDebtMember2023-09-300000939930pyx:OtherLongTermDebtMember2024-03-310000939930us-gaap:NotesPayableToBanksMember2024-09-300000939930us-gaap:NotesPayableToBanksMember2023-09-300000939930us-gaap:NotesPayableToBanksMember2024-03-310000939930pyx:DelayedDrawTermLoanFacilityCreditAgreementMemberus-gaap:SeniorNotesMember2024-09-300000939930pyx:SeniorSecuredFirstLienNotesDue2027Memberpyx:NewPyxusCreditFacilityMember2023-02-062023-02-060000939930pyx:SeniorSecuredFirstLienNotesDue2027Memberpyx:DelayedDrawTermLoanFacilityCreditAgreementMemberus-gaap:LineOfCreditMember2024-09-300000939930pyx:SeniorSecuredFirstLienNotesDue2027Memberpyx:IntabexTermLoansMember2023-02-062023-02-060000939930pyx:SeniorSecuredFirstLienNotesDue2027Memberpyx:IntabexTermLoansMember2023-02-060000939930pyx:DelayedDrawTermLoanFacilityCreditAgreementMemberus-gaap:LineOfCreditMember2024-09-300000939930pyx:TermLoanCreditAgreementMemberpyx:PyxusCreditFacilityMember2023-02-062023-02-060000939930pyx:ABLCreditFacilityMemberpyx:RevolvingLineOfCreditMember2023-10-240000939930pyx:PNCABLCreditFacilityMemberus-gaap:LineOfCreditMember2022-02-080000939930pyx:PNCABLCreditFacilityMemberpyx:RevolvingLineOfCreditMember2022-02-080000939930pyx:TermLoanCreditAgreementMemberpyx:IntabexTermLoansMemberus-gaap:BaseRateMembersrt:MinimumMember2023-02-060000939930pyx:TermLoanCreditAgreementMemberpyx:IntabexTermLoansMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MaximumMember2023-02-062023-02-060000939930pyx:TermLoanCreditAgreementMemberpyx:IntabexTermLoansMemberus-gaap:BaseRateMember2023-02-062023-02-060000939930pyx:TermLoanCreditAgreementMemberpyx:PyxusCreditFacilityMember2023-02-060000939930pyx:TermLoanCreditAgreementMemberpyx:PyxusTermLoanMemberus-gaap:BaseRateMembersrt:MinimumMember2023-02-060000939930pyx:TermLoanCreditAgreementMemberpyx:PyxusTermLoanMemberus-gaap:SecuredOvernightFinancingRateSofrOvernightIndexSwapRateMembersrt:MaximumMember2023-02-062023-02-060000939930pyx:TermLoanCreditAgreementMemberpyx:PyxusTermLoanMemberus-gaap:BaseRateMember2023-02-062023-02-060000939930pyx:A850PercentageSeniorSecuredNotesDue2027Memberus-gaap:SeniorNotesMember2023-02-060000939930pyx:SeniorSecuredFirstLienNotesDue2024Memberus-gaap:SeniorNotesMember2020-08-240000939930pyx:A850PercentageSeniorSecuredNotesDue2027Memberpyx:NewPyxusCreditFacilityMember2023-02-060000939930us-gaap:EquityMethodInvesteeMemberpyx:MonarchAlternativeCapitalLPMember2023-01-230000939930pyx:DebtRepurchaseAgreementMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-03-210000939930pyx:DebtRepurchaseAgreement2027NotesMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-03-210000939930pyx:DebtRepurchaseAgreement2027NotesMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-03-212024-03-210000939930pyx:DebtRepurchaseAgreementMemberus-gaap:SeniorNotesMember2024-03-282024-03-280000939930pyx:DebtRepurchaseAgreementMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2024-03-210000939930pyx:DebtRepurchaseAgreement2027NotesMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2024-04-120000939930pyx:DebtRepurchaseAgreement2027NotesMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2024-04-122024-04-120000939930pyx:DebtRepurchaseAgreementMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-03-310000939930pyx:DebtRepurchaseAgreementMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2024-04-120000939930pyx:DebtRepurchaseAgreementMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2024-04-122024-04-120000939930pyx:DebtRepurchaseAgreementMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodTwoMember2024-05-310000939930pyx:DebtRepurchaseAgreementMemberus-gaap:SeniorNotesMember2024-05-312024-05-310000939930pyx:DebtRepurchaseAgreement2027NotesMemberus-gaap:SeniorNotesMemberus-gaap:DebtInstrumentRedemptionPeriodThreeMember2024-08-020000939930pyx:DebtRepurchaseAgreementMemberus-gaap:SeniorNotesMember2024-08-022024-08-020000939930pyx:SeniorSecuredFirstLienNotesDue2024Memberpyx:NewPyxusCreditFacilityMember2024-09-300000939930pyx:SeniorSecuredFirstLienNotesDue2024Memberus-gaap:SeniorNotesMember2024-08-262024-08-260000939930srt:MinimumMemberus-gaap:LineOfCreditMember2024-04-012024-09-300000939930srt:MaximumMemberus-gaap:LineOfCreditMember2024-04-012024-09-300000939930us-gaap:LineOfCreditMember2024-04-012024-09-300000939930us-gaap:LineOfCreditMember2024-09-300000939930us-gaap:ForeignLineOfCreditMemberus-gaap:LineOfCreditMember2024-09-300000939930pyx:AccountsReceivableSecuritizationProgramOneMember2024-09-300000939930srt:MinimumMemberpyx:AccountsReceivableSecuritizationProgramOneMember2024-09-300000939930srt:MinimumMemberpyx:AccountsReceivableSecuritizationProgramTwoMember2024-09-3000009399302023-04-012024-03-310000939930us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000939930us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000939930us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-09-300000939930us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000939930us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000939930us-gaap:EstimateOfFairValueFairValueDisclosureMember2023-09-300000939930us-gaap:FairValueInputsLevel2Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310000939930us-gaap:FairValueInputsLevel3Memberus-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310000939930us-gaap:EstimateOfFairValueFairValueDisclosureMember2024-03-310000939930pyx:SecuritizedBeneficialInterestsMember2024-06-300000939930us-gaap:LongTermDebtMember2024-06-300000939930us-gaap:GuaranteesMember2024-06-300000939930pyx:SecuritizedBeneficialInterestsMember2023-06-300000939930us-gaap:LongTermDebtMember2023-06-300000939930us-gaap:GuaranteesMember2023-06-300000939930pyx:SecuritizedBeneficialInterestsMember2024-07-012024-09-300000939930us-gaap:GuaranteesMember2024-07-012024-09-300000939930pyx:SecuritizedBeneficialInterestsMember2023-07-012023-09-300000939930us-gaap:GuaranteesMember2023-07-012023-09-300000939930us-gaap:LongTermDebtMember2024-07-012024-09-300000939930us-gaap:LongTermDebtMember2023-07-012023-09-300000939930pyx:SecuritizedBeneficialInterestsMember2024-09-300000939930us-gaap:LongTermDebtMember2024-09-300000939930us-gaap:GuaranteesMember2024-09-300000939930pyx:SecuritizedBeneficialInterestsMember2023-09-300000939930us-gaap:LongTermDebtMember2023-09-300000939930us-gaap:GuaranteesMember2023-09-300000939930pyx:SecuritizedBeneficialInterestsMember2024-03-310000939930us-gaap:LongTermDebtMember2024-03-310000939930us-gaap:GuaranteesMember2024-03-310000939930pyx:SecuritizedBeneficialInterestsMember2023-03-310000939930us-gaap:LongTermDebtMember2023-03-310000939930us-gaap:GuaranteesMember2023-03-310000939930pyx:SecuritizedBeneficialInterestsMember2024-04-012024-09-300000939930us-gaap:GuaranteesMember2024-04-012024-09-300000939930pyx:SecuritizedBeneficialInterestsMember2023-04-012023-09-300000939930us-gaap:GuaranteesMember2023-04-012023-09-300000939930us-gaap:LongTermDebtMember2024-04-012024-09-300000939930us-gaap:LongTermDebtMember2023-04-012023-09-300000939930pyx:TaxAssessmentMemberpyx:SuitNumberThreeMember2007-10-260000939930pyx:TaxAssessmentMemberpyx:SuitNumberThreeMember2024-09-300000939930us-gaap:RestrictedStockUnitsRSUMember2023-07-012023-09-300000939930us-gaap:RestrictedStockUnitsRSUMember2023-04-012023-09-300000939930pyx:PerformancebasedStockUnitsMember2024-07-012024-09-300000939930pyx:PerformancebasedStockUnitsMember2023-07-012023-09-300000939930pyx:PerformancebasedStockUnitsMember2024-04-012024-09-300000939930pyx:PerformancebasedStockUnitsMember2023-04-012023-09-300000939930us-gaap:RestrictedStockUnitsRSUMember2024-09-300000939930pyx:PerformancebasedStockUnitsMembersrt:MinimumMember2024-04-012024-09-300000939930pyx:PerformancebasedStockUnitsMembersrt:MaximumMember2024-04-012024-09-300000939930us-gaap:RelatedPartyMember2024-07-012024-09-300000939930us-gaap:RelatedPartyMember2023-07-012023-09-300000939930us-gaap:RelatedPartyMember2024-04-012024-09-300000939930us-gaap:RelatedPartyMember2023-04-012023-09-300000939930pyx:OtherReceivablesMemberus-gaap:RelatedPartyMember2024-09-300000939930pyx:OtherReceivablesMemberus-gaap:RelatedPartyMember2023-09-300000939930pyx:OtherReceivablesMemberus-gaap:RelatedPartyMember2024-03-310000939930us-gaap:AccountsPayableMemberus-gaap:RelatedPartyMember2024-09-300000939930us-gaap:AccountsPayableMemberus-gaap:RelatedPartyMember2023-09-300000939930us-gaap:AccountsPayableMemberus-gaap:RelatedPartyMember2024-03-310000939930pyx:ContractWithCustomerLiabilityCurrentMemberus-gaap:RelatedPartyMember2024-09-300000939930pyx:ContractWithCustomerLiabilityCurrentMemberus-gaap:RelatedPartyMember2023-09-300000939930pyx:ContractWithCustomerLiabilityCurrentMemberus-gaap:RelatedPartyMember2024-03-310000939930pyx:GlendonInvestorMemberus-gaap:BeneficialOwnerMember2024-06-130000939930pyx:OwlCreekAssetManagementLPMemberus-gaap:BeneficialOwnerMember2024-08-310000939930us-gaap:CommonStockMemberpyx:CIInvestmentsInc.Member2024-08-222024-08-220000939930us-gaap:EquityMethodInvesteeMember2024-09-300000939930us-gaap:EquityMethodInvesteeMember2023-09-300000939930us-gaap:EquityMethodInvesteeMember2024-03-3100009399302024-03-282024-03-2800009399302024-05-312024-05-3100009399302024-08-022024-08-020000939930pyx:LeafSegmentMember2024-07-012024-09-300000939930pyx:LeafSegmentMember2023-07-012023-09-300000939930pyx:LeafSegmentMember2024-04-012024-09-300000939930pyx:LeafSegmentMember2023-04-012023-09-300000939930us-gaap:OperatingSegmentsMemberpyx:LeafSegmentMember2024-07-012024-09-300000939930us-gaap:OperatingSegmentsMemberpyx:LeafSegmentMember2023-07-012023-09-300000939930us-gaap:OperatingSegmentsMemberpyx:LeafSegmentMember2024-04-012024-09-300000939930us-gaap:OperatingSegmentsMemberpyx:LeafSegmentMember2023-04-012023-09-300000939930us-gaap:OperatingSegmentsMemberpyx:OtherProductsAndServicesSegmentMember2024-07-012024-09-300000939930us-gaap:OperatingSegmentsMemberpyx:OtherProductsAndServicesSegmentMember2023-07-012023-09-300000939930us-gaap:OperatingSegmentsMemberpyx:OtherProductsAndServicesSegmentMember2024-04-012024-09-300000939930us-gaap:OperatingSegmentsMemberpyx:OtherProductsAndServicesSegmentMember2023-04-012023-09-300000939930us-gaap:OperatingSegmentsMember2024-07-012024-09-300000939930us-gaap:OperatingSegmentsMember2023-07-012023-09-300000939930us-gaap:OperatingSegmentsMember2024-04-012024-09-300000939930us-gaap:OperatingSegmentsMember2023-04-012023-09-300000939930pyx:LeafSegmentMember2024-09-300000939930pyx:LeafSegmentMember2023-09-300000939930pyx:LeafSegmentMember2024-03-310000939930pyx:OtherProductsAndServicesSegmentMember2024-09-300000939930pyx:OtherProductsAndServicesSegmentMember2023-09-300000939930pyx:OtherProductsAndServicesSegmentMember2024-03-31

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 10-Q
QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE QUARTERLY PERIOD ENDED September 30, 2024.

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM _______ TO _______.
000-25734
(Commission File Number)
Image1.jpg
Pyxus International, Inc.
(Exact name of registrant as specified in its charter)

Virginia85-2386250
(State or other jurisdiction of incorporation)(I.R.S. Employer Identification No.)
 6001 Hospitality Court, Suite 100
Morrisville,North Carolina27560
(Address of principal executive offices)(Zip Code)
(919) 379-4300
(Registrant’s telephone number, including area code)

Securities registered pursuant to Section 12(b) of the Act: None

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days.    Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).    Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.   

Large accelerated filer                                           
Non-accelerated filer   
Accelerated filer   ☐                    

Smaller reporting company    
Emerging growth company    

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act).  Yes No

Indicate by check mark if the registrant has filed all documents and reports required to be filed under Sections 12, 13, or 15(d) of the Securities Exchange Act of 1934 subsequent to the distribution of securities under a plan confirmed by a court.  Yes No

As of October 31, 2024, the registrant had 24,607,791 shares outstanding of Common Stock (no par value).
1


Pyxus International, Inc. and Subsidiaries
Table of Contents
Page Number
Part I
Financial Information
Item 1.Financial Statements (Unaudited)
Item 2.
Item 3.
Item 4.
Part II
Other Information
Item 1.
Item 1A.
Item 2.
Item 5.
Item 6.





2


Part I. Financial Information

Item 1. Financial Statements

Pyxus International, Inc. and Subsidiaries
Condensed Consolidated Statements of Operations
(Unaudited)
Three Months EndedSix Months Ended
September 30,September 30,
(in thousands, except per share data)2024202320242023
Sales and other operating revenues$566,383 $624,253 $1,201,238 $1,101,345 
Cost of goods and services sold490,914 535,587 1,041,917 939,534 
Gross profit75,469 88,666 159,321 161,811 
Selling, general, and administrative expenses38,875 40,033 79,537 74,096 
Other expense, net3,292 1,089 5,922 3,713 
Restructuring and asset impairment charges224 1,254 327 1,294 
Operating income33,078 46,290 73,535 82,708 
Gain on debt retirement6,855  8,178  
Interest expense, net35,750 32,947 69,022 63,791 
Income before income taxes and other items4,183 13,343 12,691 18,917 
Income tax expense8,041 7,558 14,160 10,204 
(Income) loss from unconsolidated affiliates, net(585)(2,111)(3,148)47 
Net (loss) income(3,273)7,896 1,679 8,666 
Net (loss) income attributable to noncontrolling interests(46)(199)264 (233)
Net (loss) income attributable to Pyxus International, Inc.$(3,227)$8,095 $1,415 $8,899 
(Loss) earnings per share:
Basic$(0.12)$0.32 $0.06 $0.36 
Diluted$(0.12)$0.32 $0.06 $0.36 
Weighted average number of shares outstanding:
Basic25,825 25,000 25,683 25,000 
Diluted25,825 25,000 25,683 25,000 
See "Notes to Condensed Consolidated Financial Statements"







3


Pyxus International, Inc. and Subsidiaries
Condensed Consolidated Statements of Comprehensive (Loss) Income
(Unaudited)
Three Months EndedSix Months Ended
September 30,September 30,
(in thousands)2024202320242023
Net (loss) income$(3,273)$7,896 $1,679 $8,666 
Other comprehensive income (loss), net of tax:
Foreign currency translation adjustment278 (1,545)821 (838)
Cash flow hedges1,266 (1,000)(971)(138)
Total other comprehensive income (loss), net of tax1,544 (2,545)(150)(976)
Total comprehensive (loss) income(1,729)5,351 1,529 7,690 
Comprehensive (loss) income attributable to noncontrolling interests(46)(199)264 (233)
Comprehensive (loss) income attributable to Pyxus International, Inc.$(1,683)$5,550 $1,265 $7,923 
See "Notes to Condensed Consolidated Financial Statements"





4


Pyxus International, Inc. and Subsidiaries
Condensed Consolidated Balance Sheets
(Unaudited)
(in thousands)September 30, 2024September 30, 2023March 31, 2024
Assets
Current assets
Cash and cash equivalents$123,486 $112,098 $92,569 
Restricted cash7,446 5,572 7,224 
Trade receivables, net226,376 233,679 168,764 
Other receivables11,125 27,664 18,704 
Inventories, net974,570 877,154 931,654 
Advances to tobacco suppliers, net77,999 67,641 20,397 
Recoverable income taxes2,988 5,090 4,455 
Prepaid expenses43,095 36,844 50,185 
Other current assets18,988 15,179 16,254 
Total current assets1,486,073 1,380,921 1,310,206 
Investments in unconsolidated affiliates104,403 87,042 101,255 
Intangible assets, net31,587 36,251 33,879 
Deferred income taxes, net7,121 15,768 7,196 
Long-term recoverable income taxes4,008 3,410 2,963 
Other noncurrent assets34,916 46,206 32,617 
Right-of-use assets32,420 39,139 35,639 
Property, plant, and equipment, net136,146 133,717 134,158 
Total assets$1,836,674 $1,742,454 $1,657,913 
Liabilities and Stockholders’ Equity
Current liabilities
Notes payable$744,779 $570,036 $499,312 
Accounts payable152,594 153,152 181,247 
Advances from customers75,796 46,056 90,719 
Accrued expenses and other current liabilities103,393 93,981 96,954 
Income taxes payable13,589 12,585 8,539 
Operating leases payable8,279 8,380 8,100 
Current portion of long-term debt89 20,232 20,294 
Total current liabilities1,098,519 904,422 905,165 
Long-term taxes payable2,573 2,678 2,678 
Long-term debt489,470 573,959 497,734 
Deferred income taxes6,303 10,225 7,934 
Liability for unrecognized tax benefits12,510 20,170 17,742 
Long-term leases21,617 28,171 26,136 
Pension, postretirement, and other long-term liabilities54,923 52,816 53,701 
Total liabilities$1,685,915 $1,592,441 $1,511,090 
Commitments and contingencies
Stockholders’ equity
Common Stock—no par value:
Authorized shares (250,000 for all periods)
Issued and outstanding shares (24,608, 25,000 and 25,000)
$392,421 $390,290 $389,789 
Retained deficit(253,876)(249,055)(255,291)
Accumulated other comprehensive income7,636 4,539 7,786 
Total stockholders’ equity of Pyxus International, Inc.146,181 145,774 142,284 
Noncontrolling interests4,578 4,239 4,539 
Total stockholders’ equity150,759 150,013 146,823 
Total liabilities and stockholders’ equity$1,836,674 $1,742,454 $1,657,913 
See "Notes to Condensed Consolidated Financial Statements"


5



Pyxus International, Inc. and Subsidiaries
Condensed Consolidated Statements of Stockholders' Equity
(Unaudited)
Attributable to Pyxus International, Inc.
Accumulated Other Comprehensive Income
(in thousands)Common StockRetained
Deficit
Currency Translation AdjustmentPensions,
Net of Tax
Derivatives, Net of TaxNoncontrolling
Interests
Total Stockholders' Equity
Balance, March 31, 2024$389,789 $(255,291)$(5,692)$12,766 $712 $4,539 $146,823 
Net income— 4,642 — — — 310 4,952 
Equity-based compensation3,031 — — — — — 3,031 
Other comprehensive (loss) income, net of tax— — 543 — (2,237)— (1,694)
Balance, June 30, 2024$392,820 $(250,649)$(5,149)$12,766 $(1,525)$4,849 $153,112 
Net loss— (3,227)— — — (46)(3,273)
Dividends— — — — — (225)(225)
Equity-based compensation601 — — — — — 601 
Share repurchases(1,000)— — — — — (1,000)
Other comprehensive income, net of tax— — 278  1,266 — 1,544 
Balance, September 30, 2024$392,421 $(253,876)$(4,871)$12,766 $(259)$4,578 $150,759 


Balance, March 31, 2023$390,290 $(257,954)$(6,392)$8,335 $3,572 $3,979 $141,830 
Net income (loss)— 804 — — — (34)770 
Other comprehensive income, net of tax— — 707 — 862 — 1,569 
Balance, June 30, 2023$390,290 $(257,150)$(5,685)$8,335 $4,434 $3,945 $144,169 
Net income (loss)— 8,095 — — — (199)7,896 
Other— — — — — 493 493 
Other comprehensive loss, net of tax— — (1,545) (1,000)— (2,545)
Balance, September 30, 2023$390,290 $(249,055)$(7,230)$8,335 $3,434 $4,239 $150,013 

See "Notes to Condensed Consolidated Financial Statements"
6


Pyxus International, Inc. and Subsidiaries
Condensed Consolidated Statements of Cash Flows
(Unaudited)
Six Months Ended
September 30,
(in thousands)20242023
Operating Activities:
Net income$1,679 $8,666 
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation and amortization10,192 9,319 
Debt amortization/interest5,755 5,118 
Gain on debt retirement(8,178) 
Loss on foreign currency transactions2,514 4,551 
Equity-based compensation3,632  
(Income) loss from unconsolidated affiliates, net of dividends(3,148)13,707 
Changes in operating assets and liabilities, net
Trade and other receivables(150,636)(143,199)
Inventories and advances to tobacco suppliers(100,688)(128,596)
Deferred items(7,287)(4,902)
Recoverable income taxes448 (95)
Payables and accrued expenses(20,317)(10,251)
Advances from customers(14,072)3,559 
Prepaid expenses9,246 (712)
Income taxes5,111 (5,341)
Other operating assets and liabilities(6,764)1,840 
Other, net(7,756)(9,084)
Net cash used in operating activities$(280,269)$(255,420)
Investing Activities:
Purchases of property, plant, and equipment$(9,784)$(9,225)
Collections from beneficial interests in securitized trade receivables 101,597 79,296 
Other, net1,703 3,072 
Net cash provided by investing activities$93,516 $73,143 
Financing Activities:
Net proceeds from short-term borrowings$244,223 $192,186 
Proceeds from revolving loan facilities165,000 105,000 
Repayment of revolving loan facilities(130,000)(130,000)
Debt issuance costs(2,808)(3,851)
Repayment of long-term borrowings(55,822) 
Other, net(563)(67)
Net cash provided by financing activities$220,030 $163,268 
Effect of exchange rate changes on cash(2,138)(2,230)
Increase (decrease) in cash, cash equivalents, and restricted cash31,139 (21,239)
Cash and cash equivalents at beginning of period92,569 136,733 
Restricted cash at beginning of period7,224 2,176 
Cash, cash equivalents, and restricted cash at end of period$130,932 $117,670 
Other information:
Cash paid for income taxes, net$14,236 $6,604 
Cash paid for income taxes related to debt exchange 12,543 
Cash paid for interest, net51,966 43,881 
Noncash investing activities:
Noncash amounts obtained as a beneficial interest in exchange for transferring trade receivables in a securitization transaction116,911 83,278 
See "Notes to Condensed Consolidated Financial Statements"
7


Pyxus International, Inc. and Subsidiaries
Notes to Condensed Consolidated Financial Statements
(Unaudited)
(in thousands, except per share data)Page Number



























8


1. Basis of Presentation and Summary of Significant Accounting Policies

The accompanying condensed consolidated financial statements represent the consolidation of Pyxus International, Inc. (the "Company", "Pyxus", "we", or "us") and all companies that Pyxus directly or indirectly controls, either through majority ownership or otherwise. These condensed consolidated financial statements have been prepared in accordance with accounting principles generally accepted in the United States of America ("U.S. GAAP") for interim information and with the instructions to Form 10-Q and Regulation S-X. Accordingly, they do not include the information and footnotes required by U.S. GAAP for annual financial statements. In the opinion of management, the normal and recurring adjustments necessary for fair statement of financial position, results of operations, and cash flows at the dates and for the periods presented have been included. Intercompany accounts and transactions have been eliminated.

These condensed consolidated interim financial statements should be read in conjunction with the Company's consolidated financial statements and notes thereto included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024 filed on June 6, 2024. Due to the seasonal nature of the Company’s business, the results of operations for a fiscal quarter are not necessarily indicative of the operating results that may be attained for other quarters or a full fiscal year.

2. New Accounting Standards

Accounting Pronouncements Not Yet Adopted

In November 2023, the Financial Accounting Standards Board ("FASB") issued Accounting Standards Update ("ASU") No. 2023-07, Segment Reporting: Improvements to Reportable Segment Disclosures. This ASU amends FASB Topic 280 to permit the disclosure of multiple measures of a segment's profit or loss, and requires an entity with a single reportable segment to apply FASB Topic 280 in its entirety. In addition, this ASU requires the following new segment disclosures:

Significant segment expenses by reportable segment if regularly provided to the Chief Operating Decision Maker ("CODM") and included within the reported measure of segment profit or loss;
Other segment items, which represents the difference between reported segment revenues less the significant segment expenses less reported segment profit or loss; and
Title and position of the CODM.

Disclosures required under this new ASU and the existing segment profit or loss and assets disclosures currently required annually by FASB Topic 280 are to be disclosed in interim periods. The annual disclosure requirements are effective for the Company's fiscal year ending March 31, 2025, and the interim period disclosure requirements are effective beginning April 1, 2025. Early adoption is permitted. This new rule will result in additional disclosures for segment reporting, and does not have an impact on the Company's financial condition, results of operations, or cash flows.

In December 2023, the FASB issued ASU No. 2023-09, Income Taxes: Improvements to Income Tax Disclosures, to provide more disaggregation of income tax information mainly related to the effective tax rate reconciliation and the income taxes paid disclosure requirements. Under the new accounting rules, the tabular effective tax rate reconciliation must include specific categories with certain reconciling items based on the expected tax further disaggregated by nature and/or jurisdiction. Income taxes paid, net of refunds received, must be broken out by federal, state, and foreign taxes, and further disaggregated by individual jurisdictions based on total income taxes paid. These new annual disclosure requirements are effective for the Company's fiscal year ending March 31, 2026. Early adoption is permitted. The Company is currently evaluating the impact that this new accounting standard will have on its income tax disclosures.

In November 2024, the FASB issued ASU No. 2024-03, Disaggregation of Income Statement Expenses, which requires a tabular disclosure of relevant expense captions into prescribed natural expense categories. The annual disclosure requirements are effective for the Company’s fiscal year ending March 31, 2028, and the interim period disclosure requirements are effective beginning April 1, 2028. Early adoption is permitted. This new rule will result in additional disclosures within the footnotes to the financial statements, and is not expected to have an impact on the Company’s financial condition, results of operations, or cash flows.
9


3. Revenue Recognition

Product revenue is primarily from the sale of processed tobacco to customers. Processing and other revenues are mainly contracts to process customer-owned green tobacco. During such processing, ownership remains with the customers. All Other revenue is primarily composed of revenue from the sale of e-liquids and non-tobacco agriculture products. The following disaggregates sales and other operating revenues by major source, with the All Other category being included for purposes of reconciliation of the respective balances below of the Leaf segment (the Company's sole reportable segment) to the condensed consolidated financial statements:

Three Months EndedSix Months Ended
September 30,September 30,
2024202320242023
Leaf:
Product revenue$515,813 $585,801 $1,105,030 $1,036,739 
Processing and other revenues48,358 37,326 90,104 62,821 
Total sales and other operating revenues564,171 623,127 1,195,134 1,099,560 
All Other:
Total sales and other operating revenues2,212 1,126 6,104 1,785 
Total sales and other operating revenues$566,383 $624,253 $1,201,238 $1,101,345 

The following summarizes activity in the allowance for expected credit losses:

Three Months EndedSix Months Ended
September 30,September 30,
2024202320242023
Balance, beginning of period$(24,035)$(24,440)$(23,940)$(24,730)
Additions(227)(238)(628)(558)
Write-offs and other adjustments12 305 318 915 
Balance, end of period(24,250)(24,373)(24,250)(24,373)
Trade receivables250,626 258,052 250,626 258,052 
Trade receivables, net$226,376 $233,679 $226,376 $233,679 

4. Income Taxes

For each period presented, the Company's quarterly provision for income taxes is not calculated using the annual effective tax rate method ("AETR method"), which applies an estimated annual effective tax rate to pre-tax income or loss. As of the end of the current period, market specific factors coupled with tax rate sensitivity caused the AETR method to produce an unreliable estimate of the Company’s annual effective tax rate; therefore, the Company recorded its interim income tax provision using the discrete method, as allowed under FASB ASC 740-270, Income Taxes - Interim Reporting. Using the discrete method, the Company determined income tax expense as if each of the six-month interim periods reported were an annual period.

The effective tax rate for the six months ended September 30, 2024 and 2023 was 111.6% and 53.9%, respectively. For the six months ended September 30, 2024, the difference between the Company’s effective rate and the U.S. statutory rate of 21.0% is primarily due to U.S. taxation of foreign earnings, partially offset by foreign tax credits and increases in the Company's deferred tax valuation allowances.

The long-term liability for unrecognized tax benefits as of September 30, 2024 was $12,510 compared to $20,170 as of September 30, 2023. The decrease was primarily driven by tax settlements in Africa.
10


5. (Loss) Earnings Per Share

The calculations of basic and diluted (loss) earnings per share are based on net (loss) income divided by the basic weighted average number of common shares and diluted weighted average number of common shares outstanding, respectively. Under the treasury stock method, restricted stock units will have a dilutive effect when the respective period's average market price of the Company's common stock exceeds the assumed exercise proceeds and the average amount of cost not yet recognized. Performance based stock units are included in diluted (loss) earnings per share if the performance targets have been met at the end of the reporting period. Share-based payment awards that provide contingently issuable shares upon a performance or market condition are included in basic and diluted (loss) earnings per share only if the condition is met as of the end of the reporting period.

The following summarizes the computation of (loss) earnings per share:

Three Months EndedSix Months Ended
September 30,September 30,
2024202320242023
Net (loss) income attributable to Pyxus International, Inc.$(3,227)$8,095 $1,415 $8,899 
Basic weighted average shares outstanding25,825 25,000 25,683 25,000 
Plus: Dilutive equity awards (1)
    
Diluted weighted average shares outstanding25,825 25,000 25,683 25,000 
(Loss) earnings per share:
Basic$(0.12)$0.32 $0.06 $0.36 
Diluted$(0.12)$0.32 $0.06 $0.36 
(1) For the three and six months ended September 30, 2024, the weighted average number of outstanding restricted stock units not included in the computation of diluted earnings per share because their effect would be antidilutive is 96 and 82, respectively.

6. Restricted Cash

The following summarizes the composition of restricted cash:

September 30, 2024September 30, 2023March 31, 2024
Compensating balance for short-term borrowings$542 $516 $516 
Escrow2,955 2,389 2,647 
Grants1,857 1,342 1,375 
Other2,092 1,325 2,686 
Total$7,446 $5,572 $7,224 

7. Inventories, Net

The following summarizes the composition of inventories, net:

September 30, 2024September 30, 2023March 31, 2024
Processed tobacco$750,552 $646,757 $585,280 
Unprocessed tobacco192,758 188,489 305,928 
Other tobacco related24,725 28,814 31,213 
All Other
6,535 13,094 9,233 
Total$974,570 $877,154 $931,654 


11


8. Equity Method Investments

The following summarizes the Company's equity method investments as of September 30, 2024:

Investee NameLocationPrimary PurposeOwnership Percentage
Basis Difference(1)
Adams International Ltd.ThailandPurchase and process tobacco49%$(4,526)
Alliance One Industries India Private Ltd.IndiaPurchase and process tobacco49%(5,770)
China Brasil Tabacos Exportadora S.A.BrazilPurchase and process tobacco49%43,000 
Oryantal Tütün Paketleme Sanayi ve Ticaret A.Ş.TurkeyProcess tobacco50%(416)
Purilum, LLCU.S.Produce flavor formulations and consumable e-liquids50%4,589 
Siam Tobacco Export Corporation Ltd.ThailandPurchase and process tobacco49%(6,098)
(1) Basis differences for the Company's equity method investments were due to fair value adjustments recorded during fiscal 2021.

The following summarizes financial information for these equity method investments:

Three Months EndedSix Months Ended
September 30,September 30,
2024202320242023
Statement of operations:
Sales$86,525 $81,455 $143,296 $126,287 
Gross profit12,528 12,173 19,715 19,359 
Net income1,182 5,010 6,421 1,156 

September 30, 2024September 30, 2023March 31, 2024
Balance sheet:
Current assets$545,582 $453,711 $542,702 
Property, plant, and equipment and other assets49,755 48,315 50,925 
Current liabilities441,205 386,646 446,597 
Long-term obligations and other liabilities4,038 2,487 3,356 

9. Variable Interest Entities

The Company holds variable interests in multiple entities that primarily procure or process inventory or are securitization entities. These variable interests relate to equity investments, receivables, guarantees, and securitized receivables. The following summarizes the Company's financial relationships with its unconsolidated variable interest entities:

September 30, 2024September 30, 2023March 31, 2024
Investments in variable interest entities$97,673 $80,067 $94,609 
Receivables with variable interest entities 12,754  
Guaranteed amounts to variable interest entities (not to exceed)16,323 61,132 11,113 

12


10. Intangible Assets, Net

The gross carrying amount and accumulated amortization of intangible assets consist of the following:

September 30, 2024
 Weighted Average Remaining Useful LifeGross Carrying AmountAccumulated AmortizationIntangible Assets, Net
Intangibles subject to amortization:
Customer relationships7.9 years$26,101 $(8,882)$17,219 
Technology4.0 years12,458 (6,094)6,364 
Trade names9.9 years11,300 (3,296)8,004 
Total$49,859 $(18,272)$31,587 

September 30, 2023
 Weighted Average Remaining Useful LifeGross Carrying AmountAccumulated AmortizationIntangible Assets, Net
Intangibles subject to amortization:
Customer relationships8.9 years$26,101 $(6,707)$19,394 
Technology4.8 years13,132 (5,086)8,046 
Trade names10.9 years11,300 (2,489)8,811 
Total$50,533 $(14,282)$36,251 

March 31, 2024
Weighted Average Remaining Useful LifeGross Carrying AmountAccumulated AmortizationIntangible Assets, Net
Intangibles subject to amortization:
Customer relationships8.4 years$26,101 $(7,794)$18,307 
Technology4.4 years12,948 (5,784)7,164 
Trade names10.4 years11,300 (2,892)8,408 
Total$50,349 $(16,470)$33,879 

The following summarizes amortization expense for definite-lived intangible assets:

Three Months EndedSix Months Ended
September 30,September 30,
2024202320242023
Amortization expense$1,140 $1,160 $2,292 $2,321 

13


11. Debt Arrangements

The following summarizes debt and notes payable:

(in thousands)Interest RateSeptember 30, 2024September 30, 2023March 31, 2024
Senior secured credit facilities:
ABL Credit Facility8.6 %
(1)
$35,000 $ $ 
Senior secured notes:
10.0% Notes Due 2024
10.0 %
(1)
 20,085 20,247 
8.5% Notes Due 2027 (2)
8.5 %
(1)
145,445 254,076 178,146 
Senior secured term loans:
Intabex Term Loans (3)
13.6 %
(1)
186,886 186,424 186,659 
Pyxus Term Loans (4)
13.6 %
(1)
122,139 133,170 132,819 
Other Debt:
  Other long-term debt8.7 %
(1)
89 436 157 
   Notes payable (5)
9.9 %
(1)
744,779 570,036 499,312 
    Total debt$1,234,338 $1,164,227 $1,017,340 
Short-term (5)
$744,779 $570,036 $499,312 
Long-term:
Current portion of long-term debt$89 $20,232 $20,294 
Long-term debt489,470 573,959 497,734 
Total$489,559 $594,191 $518,028 
Letters of credit$7,785 $6,783 $5,070 
(1) Weighted average rate for the trailing twelve months ended September 30, 2024 or, for indebtedness outstanding only during a portion of such twelve-month period, for the portion of such period that such indebtedness was outstanding.
(2) Balance of $145,445 is net of a debt discount of $2,894. Total repayment at maturity is $148,339.
(3) Balance of $186,886 is net of a debt discount of $2,147. Total repayment at maturity is $189,033, which includes a $2,000 exit fee payable upon repayment.
(4) Balance of $122,139 is net of a debt premium of $1,934. Total repayment at maturity is $120,205.
(5) Primarily foreign seasonal lines of credit.
14


Outstanding Senior Secured Debt

ABL Credit Facility
On February 8, 2022, the Company’s wholly owned subsidiary, Pyxus Holdings, Inc. ("Pyxus Holdings"), certain subsidiaries of Pyxus Holdings (together with Pyxus Holdings, the "Borrowers"), and the Company and its wholly owned subsidiary, Pyxus Parent, Inc. ("Pyxus Parent"), as parent guarantors, entered into an ABL Credit Agreement (as amended, the "ABL Credit Agreement"), dated as of February 8, 2022, by and among Pyxus Holdings, as Borrower Agent, the Borrowers and parent guarantors party thereto, the lenders party thereto, and PNC Bank, National Association, as Administrative Agent and Collateral Agent, to establish an asset-based revolving credit facility (the "ABL Credit Facility"), the proceeds of which may be used to refinance existing senior bank debt, pay fees and expenses related to the ABL Credit Facility, partially fund capital expenditures, and provide for the ongoing working capital needs of the Borrowers. The ABL Credit Agreement was amended on May 23, 2023 to extend the maturity of the ABL Credit Facility to February 8, 2027. The ABL Credit Agreement was amended on October 24, 2023 to, among other things increase the aggregate amount of the revolving loan commitments under the ABL Credit Facility to $120,000. A detailed description of the ABL Credit Agreement is included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024.

The ABL Credit Facility may be used for revolving credit loans and letters of credit from time to time up to an initial maximum principal amount of $120,000, subject to the limitations described in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024. The ABL Credit Facility includes a $20,000 uncommitted accordion feature that permits Pyxus Holdings, under certain conditions, to solicit the lenders under the ABL Credit Facility to provide additional revolving loan commitments to increase the aggregate amount of the revolving loan commitments under the ABL Credit Facility not to exceed a maximum principal amount of $140,000. At September 30, 2024, the Borrowers and the parent guarantors under the ABL Credit Agreement were in compliance with the covenants under the ABL Credit Agreement.

Intabex Term Loans
On February 6, 2023, Pyxus Holdings entered into the Intabex Term Loan Credit Agreement, dated as of February 6, 2023 (the "Intabex Term Loan Credit Agreement"), by and among, Pyxus Holdings, the guarantors party thereto, the lenders party thereto and Alter Domus (US) LLC ("Alter Domus"), as administrative agent and senior collateral agent. The Intabex Term Loan Credit Agreement established a term loan credit facility in an aggregate principal amount of approximately $189,033 (the "Intabex Credit Facility"), under which term loans in the full aggregate principal amount of the Intabex Credit Facility (the "Intabex Term Loans") were deemed made in exchange for certain outstanding term debt of Pyxus Holdings, accrued and unpaid PIK interest thereon, and related fees. The Intabex Term Loans bear interest, at Pyxus Holdings’ option, at either (i) a term SOFR rate (subject to a floor of 1.5%) plus 8.0% per annum or (ii) an alternate base rate plus 7.0% per annum. The Intabex Term Loans are stated to mature on December 31, 2027. A detailed description of the Intabex Term Loan Credit Agreement is included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024. At September 30, 2024, Pyxus Holdings and the guarantors under the Intabex Term Loan Credit Agreement were in compliance with all covenants under the Intabex Term Loan Credit Agreement.

Pyxus Term Loans
On February 6, 2023, Pyxus Holdings entered into the Pyxus Term Loan Credit Agreement, dated as of February 6, 2023 (the "Pyxus Term Loan Credit Agreement"), by and among, Pyxus Holdings, the guarantors party thereto, the lenders party thereto and Alter Domus, as administrative agent and senior collateral agent, to establish a term loan credit facility in an aggregate principal amount of approximately $130,550 (the "Pyxus Credit Facility"), under which term loans in the full aggregate principal amount of the Pyxus Credit Facility (the "Pyxus Term Loans") were deemed made in exchange for certain outstanding term debt of Pyxus Holdings and applicable accrued and unpaid PIK interest thereon. The Pyxus Term Loans bear interest, at Pyxus Holdings’ option, at either (i) a term SOFR rate (subject to a floor of 1.5%) plus 8.0% per annum or (ii) an alternate base rate plus 7.0% per annum. The Pyxus Term Loans are stated to mature on December 31, 2027. A detailed description of the Pyxus Term Loan Credit Agreement is included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024. At September 30, 2024, Pyxus Holdings and the guarantors under the Pyxus Term Loan Credit Agreement were in compliance with all covenants under the Pyxus Term Loan Credit Agreement.

8.50% Senior Secured Notes due 2027
Pursuant to an exchange offer made by Pyxus Holdings and accepted by holders of approximately 92.7% of the aggregate principal amount of the outstanding 10.0% Senior Secured First Lien Notes due 2024 issued by Pyxus Holdings (the "2024 Notes") pursuant to that certain Indenture, dated as of August 24, 2020 (the "2024 Notes Indenture"), by and among Pyxus Holdings, the guarantors party thereto and the trustee, collateral agent, registrar and paying agent thereunder, on February 6, 2023, Pyxus Holdings issued approximately $260,452 in aggregate principal amount of 8.5% Senior Secured Notes due December 31, 2027 (the "2027 Notes") to the exchanging holders of the 2024 Notes for an equal principal amount of 2024 Notes. The 2027 Notes were issued pursuant to the Indenture, dated as of February 6, 2023 (the "2027 Notes Indenture"), among Pyxus Holdings, the guarantors party thereto, and Wilmington Trust, National Association, as trustee, and Alter Domus, as collateral agent. The 2027 Notes bear interest at a rate of 8.5% per annum, which interest is computed on the basis of a 360-
15


day year comprised of twelve 30-day months. The 2027 Notes are stated to mature on December 31, 2027. A detailed description of the 2027 Notes and the 2027 Notes Indenture is included in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024. At September 30, 2024, Pyxus Holdings and the guarantors of the 2027 Notes were in compliance with all covenants under the 2027 Notes Indenture.

Related Party Transactions

Based on a Schedule 13D/A filed with the SEC on March 25, 2024, by Monarch Alternative Capital LP (the "Monarch Investor"), MDRA GP LP and Monarch GP LLC, the Monarch Investor reported beneficial ownership of 6,125 shares of the Company’s common stock, representing approximately 24.9% of the outstanding shares of the Company’s common stock. An individual designated by the Monarch Investor serves as a director of Pyxus.

On March 21, 2024, Pyxus Holdings entered into an agreement (the "Debt Repurchase Agreement") with funds affiliated with the Monarch Investor to purchase $77,922 of aggregate principal amount of their holdings in the 2027 Notes for $60,000, a 23.0% discount to par value, plus accrued and unpaid interest and specified customary fees. The purchase of $77,922 aggregate principal amount of the 2027 Notes for a total of $62,339 (including fees and accrued and unpaid interest) was completed on March 28, 2024.

The Debt Repurchase Agreement also included the right of Pyxus Holdings, at its option, to purchase from such holders an additional $34,191 aggregate principal amount of the 2027 Notes for $26,327, a 23.0% discount to par value, plus accrued and unpaid interest, and $10,345 aggregate principal amount of the Pyxus Term Loans for $9,104, a 12.0% discount to par value, plus accrued and unpaid interest. On April 12, 2024, Pyxus Holdings exercised its rights to complete these repurchases by September 30, 2024.

On May 31, 2024, Pyxus Holdings completed the purchase of $10,345 of aggregate principal amount of the Pyxus Term Loans for a total of $9,435 (including accrued and unpaid interest).

On August 2, 2024, Pyxus Holdings completed the purchase of $34,191 of aggregate principal amount of the 2027 Notes for a total of $26,707 (including accrued and unpaid interest).

The Debt Repurchase Agreement and the transactions contemplated thereunder were approved and determined to be on terms and conditions at least as favorable to the Company and its subsidiaries as could reasonably have been obtained in a comparable arm's-length transaction with an unaffiliated party by a majority of the disinterested members of the Board of Directors of Pyxus.

Other Outstanding Debt

2024 Notes
The 2024 Notes bore interest at a rate of 10.0% per year, payable semi-annually in arrears in cash on February 15 and August 15 of each year. On August 26, 2024, upon maturity of the 2024 Notes, Pyxus Holdings paid $20,442, which included $51 for accrued and unpaid interest, to retire the 2024 Notes.

Foreign Seasonal Lines of Credit
Excluding long-term credit agreements, the Company typically finances its non-U.S. operations with uncommitted short-term seasonal lines of credit arrangements with a number of banks. These operating lines are generally seasonal in nature, typically extending for a term of 180 days to 365 days corresponding to the tobacco crop cycle in that location. These facilities are typically uncommitted in that the lenders have the unilateral right to cease making loans and demand repayment of loans at any time or at specified dates. These loans are generally renewed at the outset of each tobacco season. Certain of the foreign seasonal lines of credit are secured by trade receivables and inventories as collateral and are guaranteed by the Company and certain of its subsidiaries. As of September 30, 2024, the total borrowing capacity under individual foreign seasonal lines of credit range up to $170,000. As of September 30, 2024, the aggregate amount available for borrowing under the seasonal lines of credit was $175,431. At September 30, 2024, the Company was permitted to borrow under foreign seasonal lines of credit up to a total $885,218, subject to limitations under the ABL Credit Agreement and the agreements governing the Intabex Term Loans, the Pyxus Term Loans and the 2027 Notes. At September 30, 2024, $542 of cash was held on deposit as a compensating balance. At September 30, 2024, the Company, and its subsidiaries, were in compliance with the covenants associated with its short-term seasonal lines of credit.

16


12. Securitized Receivables

The Company sells trade receivables to unaffiliated financial institutions under various accounts receivable securitization facilities, two of which are subject to annual renewal.

Under the first facility, with Finacity Corporation (the "Finacity Facility"), the Company continuously sells a designated pool of trade receivables to a special purpose entity, which sells 100% of the receivables to an unaffiliated financial institution. Following the sale and transfer of the receivables to the special purpose entity, the receivables are isolated from the Company and its affiliates, and effective control of the receivables is passed to the unaffiliated financial institution, which has all rights, including the right to pledge or sell the receivables. This facility requires a minimum level of deferred purchase price be retained by the Company in connection with the sales of the receivables to the unaffiliated financial institution. The Company continues to service, administer, and collect the receivables on behalf of the special purpose entity and receives a servicing fee of 0.5% of serviced receivables per annum. As the Company estimates the expected fee it receives in return for its obligation to service these receivables is at fair value, no servicing assets or liabilities are recognized. Servicing fees are recorded as a reduction of selling, general, and administrative expenses within the condensed consolidated statements of operations. As of September 30, 2024, the investment limit of this facility was $120,000 of trade receivables.

Under the second facility, the Company offers trade receivables for sale to an unaffiliated financial institution, which are then subject to acceptance by the unaffiliated financial institution. Following the sale and transfer of the receivables to the unaffiliated financial institution, the receivables are isolated from the Company and its affiliates, and effective control of the receivables is passed to the unaffiliated financial institution, which has all rights, including the right to pledge or sell the receivables. Although the Company continues to service, administer, and collect the receivables on behalf of the unaffiliated financial institution, the Company does not receive a servicing fee, and as a result, has established a servicing liability based upon unobservable inputs, primarily discounted cash flow. As of September 30, 2024, the investment limit under the second facility was $130,000 of trade receivables.

As servicer for the Finacity Facility and the second facility, the Company may receive funds that are due to the unaffiliated financial institutions which are net settled on the next settlement date. As of September 30, 2024 and 2023, and March 31, 2024, trade receivables, net in the condensed consolidated balance sheets has been reduced by $11,093, $10,014, and $15,036 as a result of the net settlement, respectively. As of September 30, 2024 and March 31, 2024, accrued expenses and other current liabilities in the consolidated balance sheets includes $1,735 and $10,279 of net payables for the Finacity Facility. Refer to "Note 15. Fair Value Measurements" for additional information.

Under the other facilities, the Company offers trade receivables for sale to unaffiliated financial institutions, which are then subject to acceptance by the unaffiliated financial institutions. Following the sale and transfer of the receivables to the unaffiliated financial institution, the receivables are isolated from the Company and its affiliates, and effective control of the receivables is passed to the unaffiliated financial institution, which has all rights, including the right to pledge or sell the receivables. As of September 30, 2024, the investment limits under these other facilities were variable based on qualifying sales.

The following summarizes the Company's accounts receivable outstanding in the securitization facilities, which represents trade receivables sold into the program that have not been collected from the customer, and related beneficial interests, which represents the Company's residual interest in receivables sold that have not been collected from the customer:

September 30, 2024September 30, 2023March 31, 2024
Receivables outstanding in facility$126,298 $177,932 $170,267 
Beneficial interests11,093 24,393 15,036 
17



Cash proceeds from the sale of trade receivables is comprised of a combination of cash and a deferred purchase price receivable. Deferred purchase price receivable is realized after the collection of the underlying trade receivables sold by the purchasers. The following summarizes the Company's cash purchase price and deferred purchase price:

Six Months Ended
September 30,
20242023
Cash proceeds:
Cash purchase price$390,348 $344,823 
Deferred purchase price101,597 79,296 

13. Guarantees

In certain markets, the Company guarantees bank loans for suppliers to finance their crops. The Company also guarantees bank loans of certain unconsolidated subsidiaries. The following summarizes amounts guaranteed and the fair value of those guarantees:

September 30, 2024September 30, 2023March 31, 2024
Amounts guaranteed (not to exceed)$47,461 $93,554 $97,411 
Amounts outstanding under guarantee (1)
22,700 18,819 71,427 
Fair value of guarantees284 1,458 5,097 
Amounts due to local banks on behalf of suppliers for government subsidized rural credit financing101 68 34,571 
(1) Most of the guarantees outstanding at September 30, 2024 expire within one year.

14. Derivative Financial Instruments

The Company uses forward or option currency contracts to manage risks associated with foreign currency exchange rates on foreign operations. These contracts are for green tobacco purchases, processing costs, and selling, general, and administrative expenses. The Company recorded a net loss of $412 and net gain of $439 from its derivative financial instruments in cost of goods and services sold for the three and six months ended September 30, 2024, respectively. The Company recorded a net gain of $1,386 and $2,820 from its derivative financial instruments in cost of goods and services sold for the three and six months ended September 30, 2023, respectively.

As of September 30, 2024 and 2023, the Company recorded current derivative assets of $685 and $132 within other current assets, respectively, and current derivative liabilities of $490 and $78 within accrued expenses and other current liabilities, respectively. Refer to "Note 15. Fair Value Measurements" for additional information.

The following summarizes the U.S. Dollar notional amount of derivative contracts outstanding:

September 30, 2024September 30, 2023March 31, 2024
U.S. Dollar notional outstanding$39,600 $14,327 $ 

18


15. Fair Value Measurements

The following summarizes the financial assets and liabilities measured at fair value on a recurring basis:    

September 30, 2024September 30, 2023March 31, 2024
Level 2Level 3Total
at Fair
Value
Level 2Level 3Total
at Fair
Value
Level 2Level 3Total
at Fair
Value
Financial Assets:
Derivative financial instruments$685 $ $685 $132 $ $132 $ $ $ 
Securitized beneficial interests 11,093 11,093  24,393 24,393  15,036 15,036 
Total assets$685 $11,093 $11,778 $132 $24,393 $24,525 $ $15,036 $15,036 
Financial Liabilities:
Derivative financial instruments$490 $ $490 $78 $ $78 $ $ $ 
Long-term debt(1)
418,849 91 418,940 481,248 507 481,755 462,987 160 463,147 
Guarantees 284 284  1,458 1,458  5,097 5,097 
Total liabilities$419,339 $375 $419,714 $481,326 $1,965 $483,291 $462,987 $5,257 $468,244 
(1) This fair value measurement disclosure does not affect the condensed consolidated balance sheets.

The following summarizes the reconciliation of changes in Level 3 instruments measured on a recurring basis:

Three Months Ended
September 30, 2024September 30, 2023
Securitized Beneficial InterestsLong-Term DebtGuaranteesSecuritized Beneficial InterestsLong-Term DebtGuarantees
Beginning balance$25,640 $160 $2,611 $19,641 $509 $5,764 
Issuances of sales of receivables/guarantees57,410 — 392 47,637 — 1,200 
Settlements(69,296)(69)(1,680)(40,198)(2)(4,206)
Losses recognized in earnings(2,661) (1,039)(2,687) (1,300)
Ending balance$11,093 $91 $284 $24,393 $507 $1,458 

Six Months Ended
September 30, 2024September 30, 2023
Securitized Beneficial InterestsLong-Term DebtGuaranteesSecuritized Beneficial InterestsLong-Term DebtGuarantees
Beginning balance$15,036 $160 $5,097 $19,522 $514 $5,262 
Issuances of sales of receivables/guarantees118,439 — 1,330 84,277 — 2,254 
Settlements(114,529)(69)(2,395)(73,381)(7)(4,761)
Losses recognized in earnings(7,853) (3,748)(6,025) (1,297)
Ending balance$11,093 $91 $284 $24,393 $507 $1,458 

For the six months ended September 30, 2024 and 2023, the impact to earnings attributable to the change in unrealized losses on securitized beneficial interests was $961 and $1,230, respectively. Gains and losses included in earnings are reported in other expense, net.

16. Contingencies and Other Information

Brazilian Tax Credits
The government in the Brazilian State of Parana ("Parana") issued a tax assessment on October 26, 2007 with respect to local intrastate trade tax credits that result primarily from tobacco transferred between states within Brazil. At September 30, 2024, the assessment for intrastate trade tax credits taken is $2,423 and the total assessment including penalties and interest is $10,095. The Company believes it has properly complied with Brazilian law and will contest any assessment through the
19


judicial process. Should the Company lose in the judicial process, the loss of the intrastate trade tax credits would have a material impact on the financial statements of the Company.

Other Matters
In addition to the above-mentioned matters, the Company or certain of its subsidiaries are involved in other litigation or legal matters incidental to their business activities, including tax matters. While the outcome of these matters cannot be predicted with certainty, they are being vigorously defended and the Company does not currently expect that any of them will have a material adverse effect on its business or financial position. However, should one or more of these matters be resolved in a manner adverse to its current expectation, the effect on the Company’s results of operations for a particular fiscal reporting period could be material.

17. Equity-Based Compensation

Pursuant to the Pyxus International, Inc. Amended and Restated 2020 Incentive Plan (the "Incentive Plan"), the Company granted time-vesting restricted stock units, with the vesting of these restricted stock units being subject to continued employment through specified dates and the condition that the Company’s common stock be listed for trading on a national securities exchange or an approved foreign securities exchange by March 31, 2028 (the "Listing Condition"). On May 10, 2024 (the "Modification Date"), the time-vesting restricted stock units granted under the Incentive Plan that were outstanding immediately prior to that date were amended to extend the period by which the Listing Condition must be satisfied for the vesting of such restricted stock units from March 31, 2028 to March 31, 2031 and to provide that the Listing Condition shall be deemed to be satisfied on March 31, 2031 regardless of whether the Company’s common stock has been listed by that date on a national securities exchange or foreign securities exchange and would vest earlier upon the occurrence of a "Change in Control" (as defined in the Incentive Plan) as a result of a merger, consolidation, share exchange or sale of all or substantially all of the assets of the Company. On the Modification Date, the amended Listing Condition was rendered nonsubstantive, and recipients of all such outstanding time-vesting restricted stock units had satisfied the continued service requirement, meaning the then-outstanding restricted stock units were fully earned for vesting. During the three and six months ended September 30, 2024, the Company recognized total equity-based compensation expense of $601 and $3,632, respectively, which is recorded in selling, general, and administrative expenses within the condensed consolidated statements of operations. The modified time-vesting restricted stock units accounted for $3,263 of the total equity-based compensation recognized year-to-date to reflect the cumulative catch-up required on the Modification Date.

The following summarizes the Company's equity awards granted:

Three Months EndedSix Months Ended
September 30,September 30,
(in thousands, except grant date fair value)2024202320242023
Restricted stock units
Number granted39  807  
Weighted average grant date fair value$3.00 $ $3.48 $ 
Performance-based stock units
Number granted (at target performance level)29  605  
Weighted average grant date fair value$4.36 $ $4.36 $ 

Restricted stock units granted under the Incentive Plan during the three and six months ended September 30, 2024 are earned ratably over a three-year period, and will vest, subject to continued employment, upon the earlier of March 31, 2031 or the occurrence of a liquidity event as defined under the terms of the restricted stock unit award agreement. Unrecognized compensation costs for restricted stock units is $2,435 as of September 30, 2024, and is expected to be recognized over a weighted average period of 2.53 years, representing the remaining service period related to the awards, subject to adjustments for actual forfeitures.

Under the terms of the performance-based stock units, the amount of shares to be issued (ranging from 0% to 200% of the number of shares to be issued at the target performance level) will be contingent upon the per share price achieved in a liquidity event (as defined under the terms of the performance-based stock unit award agreement), subject to continued employment through the date of a liquidity event. The contingent liquidity event is not probable as of September 30, 2024, and accordingly, no equity-based compensation expense has been recognized for the performance-based stock units granted during the period.

20


18. Related Party Transactions

The Company engages in transactions with its equity method investees primarily for the procuring and processing of inventory. The following summarizes activities with the Company's equity method investees:

Three Months EndedSix Months Ended
September 30,September 30,
2024202320242023
Sales$3,966 $10,399 $14,541 $21,217 
Purchases63,408 63,110 98,294 101,899 
Dividends received 13,660  13,660 

The Company included the following related party balances in its condensed consolidated balance sheets:

September 30, 2024September 30, 2023March 31, 2024Location in Condensed Consolidated Balance Sheet
Accounts receivable, related parties$50 $12,927 $50 Other receivables
Accounts payable, related parties44,878 46,987 35,396 Accounts payable
Advances from related parties42 3,832 12,533 Advances from customers

Transactions with Significant Shareholders
Based on a Schedule 13D/A filed with the SEC on June 13, 2024 by Glendon Capital Management, L.P. (the "Glendon Investor"), Holly Kim Olsen, Glendon Opportunities Fund, L.P. and Glendon Opportunities Fund II, L.P., the Glendon Investor reported beneficial ownership of 8,315 shares of the Company’s common stock, representing approximately 33.8% of the outstanding shares of the Company’s common stock. A representative of the Glendon Investor serves as a director of Pyxus. Based on a Schedule 13G/A filed with the SEC on September 3, 2024 by Owl Creek Asset Management, L.P. and Jeffrey A. Altman, Owl Creek Asset Management, L.P. is the investment manager of certain funds and reported beneficial ownership of 3,865 shares of the Company’s common stock on August 31, 2024, representing approximately 15.7% of the outstanding shares of the Company’s common stock. Funds managed by the Glendon Investor, funds managed by the Monarch Investor, and funds managed by Owl Creek Asset Management, L.P., (such funds are collectively referred to as the "Investor-Affiliated Funds") were holders, in part, of the Intabex Term Loans, the Pyxus Term Loans and the 2027 Notes, which are described in "Note 11. Debt Arrangements," during the six months ended September 30, 2024.

On August 21, 2024, the Company entered into a privately negotiated transaction with CI Investments, Inc. ("CI Investments"), which at that time was a beneficial owner of greater than five percent of the Company's common stock outstanding, to repurchase 392 (which amount is presented in thousands) shares of its common stock for approximately $1,000, inclusive of broker commission fees, which transaction was completed on August 22, 2024. This transaction was approved, and determined to be on terms and conditions at least as favorable to the Company and its subsidiaries as could reasonably have been obtained in a comparable arm's-length transaction with an unaffiliated party, by a majority of the disinterested members of the Board of Directors of Pyxus. Following the completion of this transaction and other contemporaneous dispositions of the Company’s common stock by CI Investments, CI Investments ceased to be a beneficial owner of more than five percent of the Company's common stock outstanding.

Accrued expenses and other current liabilities as presented in the condensed consolidated balance sheets as of September 30, 2024 and 2023, and March 31, 2024, includes $1,624, $9,480, and $4,239, respectively, of interest payable to Investor-Affiliated Funds and CI Investments (applicable only for the periods in which CI Investments was a beneficial owner of more than five percent of the Company's common stock outstanding). Interest expense as presented in the condensed consolidated statements of operations includes $5,945 and $13,206 for the three and six months ended September 30, 2024, respectively, and $10,294 and $20,369 for the three and six months ended September 30, 2023, respectively, that relates to the Investor-Affiliated Funds and CI Investments (applicable only for the periods in which CI Investments was a beneficial owner of more than five percent of the Company's common stock outstanding).

The holders of senior debt that are parties to the Debt Repurchase Agreement entered into on March 21, 2024 are funds affiliated with the Monarch Investor and of which the Monarch Investor is the investment advisor. The Debt Repurchase Agreement and the transactions contemplated thereby, including the exercise by Pyxus Holdings of its right to purchase the Pyxus Term Loans and additional 2027 Notes thereunder on April 12, 2024, were approved, and determined to be on terms and conditions at least as favorable to the Company and its subsidiaries as could reasonably have been obtained in a comparable arm's length transaction with an unaffiliated party, by a majority of the disinterested members of the Board of Directors of
21


Pyxus. Under the terms of the Debt Repurchase Agreement, the Company has paid the following amounts to funds affiliated with the Monarch Investor:

On March 28, 2024, the Company paid a total of $62,339, which included $1,849 of accrued and unpaid interest and $490 in other fees, to retire $77,922 of aggregate principal amount of the 2027 Notes.
On May 31, 2024, the Company paid a total of $9,435, which included $332 of accrued and unpaid interest, to retire $10,345 of aggregate principal amount of the Pyxus Term Loans.
On August 2, 2024, the Company paid a total of $26,707, which included $379 of accrued and unpaid interest, to retire $34,191 of aggregate principal amount of the 2027 Notes.

Upon completion of the transactions under the Debt Repurchase Agreement, the Monarch Investor is no longer a holder of the 2027 Notes and the Pyxus Term Loans. The Monarch Investor remains a related party as a holder of the Intabex Term Loan and a beneficial owner of more than five percent of the outstanding shares of common stock of the Company.

19. Segment Information

The following summarizes segment information, with the All Other category being included for purposes of reconciliation of the respective balances of the Leaf segment (the Company's sole reportable segment) to the condensed consolidated financial statements:

Three Months EndedSix Months Ended
September 30,September 30,
2024202320242023
Sales and other operating revenues:
Leaf$564,171 $623,127 $1,195,134 $1,099,560 
All Other2,212 1,126 6,104 1,785 
Consolidated sales and other operating revenues$566,383 $624,253 $1,201,238 $1,101,345 
Segment operating income (loss):
Leaf$36,283 $50,309 $78,765 $88,238 
All Other(2,981)(2,765)(4,903)(4,236)
Segment operating income33,302 47,544 73,862 84,002 
Restructuring and asset impairment charges224 1,254 327 1,294 
Consolidated operating income$33,078 $46,290 $73,535 $82,708 

September 30, 2024September 30, 2023March 31, 2024
Segment assets:
Leaf$1,798,849 $1,697,063 $1,616,486 
All Other37,825 45,391 41,427 
Total assets$1,836,674 $1,742,454 $1,657,913 

22


Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

Forward-Looking Statements
Readers are cautioned that the statements contained in this report regarding expectations of our performance or other matters that may affect our business, results of operations, or financial condition are "forward-looking statements" as defined in the Private Securities Litigation Reform Act of 1995. These statements, which are based on current expectations of future events, may be identified by the use of words such as "guidance", "strategy," "expects," "continues," "plans," "anticipates," "believes," "will," "estimates," "intends," "projects," "goals," "targets," and other words of similar meaning. These statements also may be identified by the fact that they do not relate strictly to historical or current facts. If underlying assumptions prove inaccurate, or if known or unknown risks or uncertainties materialize, actual results could vary materially from those anticipated, estimated, or projected. These risks and uncertainties include those discussed in this Quarterly Report on Form 10-Q, in our Annual Report on Form 10-K for the year ended March 31, 2024 and in our other filings with the Securities and Exchange Commission. These risks and uncertainties include: our reliance on a small number of significant customers; continued vertical integration by our customers; global shifts in sourcing customer requirements; shifts in the global supply and demand position for tobacco products; variation in our financial results due to growing conditions, customer indications and other factors; loss of confidence in us by our customers, farmers and other suppliers; migration of suppliers who have historically grown tobacco and from whom we have purchased tobacco toward growing other crops; risks related to our advancement of inputs to tobacco suppliers to be settled upon the suppliers delivering us unprocessed tobacco at the end of the growing season; risks that the tobacco we purchase directly from suppliers will not meet our customers’ quality and quantity requirements; weather and other environmental conditions that can affect the marketability of our inventory; international business risks, including unsettled political conditions, uncertainty in the enforcement of legal obligations, including the collection of accounts receivable, fraud risks, expropriation, import and export restrictions, exchange controls, inflationary economies, currency risks and risks related to the restrictions on repatriation of earnings or proceeds from liquidated assets of foreign subsidiaries; many of our operations are located in jurisdictions that pose a high risk of potential violations of the Foreign Corrupt Practices Act; risks and uncertainties related to geopolitical conflicts, including conflict in the Middle East and disruptions affecting Red Sea shipping; impacts of international sanctions on our ability to sell or source tobacco in certain regions; exposure to foreign tax regimes in which the rules are not clear, are not consistently applied and are subject to sudden change; fluctuations in foreign currency exchange and interest rates; competition with the other primary global independent leaf tobacco merchant and independent leaf merchants; disruption, failure or security breaches of our information technology systems and other cybersecurity risks; continued high inflation; regulations regarding environmental matters; risks related to our capital structure, including risks related to our significant debt and our ability to continue to finance our non-U.S. local operations with uncommitted short-term operating credit lines at the local level; our ability to continue to access capital markets to obtain long-term and short-term financing; potential failure of foreign banks in which our subsidiaries maintain deposits or the failure by such banks to transfer funds or honor withdrawals; the risk that, because our ability to generate cash depends on many factors beyond our control, we may be unable to generate the significant amount of cash required to service our indebtedness; our ability to refinance our current credit facilities at the same availability or at similar or reduced interest rates; failure to achieve our stated goals, which may adversely affect our liquidity; developments with respect to our liquidity needs and sources of liquidity; the volatility and disruption of global credit markets; failure by counterparties to derivative transactions to perform their obligations; increasing scrutiny and changing expectations from governments, as well as other stakeholders such as investors and customers, with respect to our environmental, social and governance policies, including sustainability policies; inherent risk of exposure to product liability claims, regulatory action and litigation facing our e-liquids business if its products are alleged to have caused significant loss, injury, or death; certain shareholders have the ability to exercise controlling influence on various corporate matters; reductions in demand for consumer tobacco products; risks and uncertainties related to pandemics or other widespread health crises and any related shipping constraints, labor shortages and supply-chain impacts; legislative and regulatory initiatives that may reduce consumption of consumer tobacco products and demand for our services and increase regulatory burdens on us or our customers; government actions that significantly affect the sourcing of tobacco, including governmental actions to identify and assess crop diversification initiatives and alternatives to leaf tobacco growing in countries whose economies depend upon tobacco production; governmental investigations into the Company's business activities, including but not limited to, leaf tobacco industry buying and other payment practices; and impact of potential regulations to prohibit the sale of cigarettes in the United States other than low-nicotine cigarettes.

We do not undertake to update any forward-looking statements that we may make from time to time except to the extent required by law.

Overview
Pyxus is a global agricultural company with businesses having more than 150 years of experience delivering value-added products and services to businesses and customers. The Company is a trusted provider of responsibly sourced, independently verified, sustainable, and traceable products and ingredients.

23


Executive Summary
Through the first six months of the fiscal year, sales and other operating revenues increased $99.8 million, or 9.1%, to $1,201.2 million for the six months ended September 30, 2024 compared to $1,101.4 million for the six months ended September 30, 2023. This increase was due to a 15.6% increase in average sales prices driven by higher tobacco prices, despite a 7.9% decrease in kilo volumes sold. Gross profit as a percent of sales decreased from 14.7% for the six months ended September 30, 2023 to 13.3% for the six months ended September 30, 2024 due mainly to regional mix from the El Niño weather effects on Africa and South America.

The ongoing Red Sea conflict, Typhoon Yagi in Southeast Asia in September 2024, and monsoon rains in India and Bangladesh during August and September 2024 contributed to shipping constraints, including vessel and equipment availability, port congestion, and rising freight costs, and undersupply conditions throughout the first half of the fiscal year.

We completed our crop purchases in the southern hemisphere and commenced crop purchases in certain markets in the northern hemisphere during the second quarter. We continued to experience elevated prices for green tobacco from continued undersupply conditions and inflation. As of September 30, 2024, our inventory was $974.6 million and our uncommitted inventory was $16.7 million. Despite purchasing more expensive green tobacco, our disciplined focus on reducing long-term debt has resulted in a total reduction of $142.8 million of aggregate principal amount of long-term debt since March 2024.



24


Results of Operations
Three Months Ended September 30, 2024 and 2023
Three Months Ended September 30,
Change
(in millions, except per kilo amounts)20242023$%
Consolidated:
Sales and other operating revenues$566.3 $624.3 (58.0)(9.3)
Cost of goods and services sold490.9 535.5 (44.6)(8.3)
Gross profit75.4 88.7 (13.3)(15.0)
Gross profit as a percent of sales13.3 %14.2 %
Selling, general, and administrative expenses$38.8 $40.0 (1.2)(3.0)
Other expense, net3.3 1.1 2.2 200.0 
Restructuring and asset impairment charges0.2 1.3 (1.1)(84.6)
Operating income*33.0 46.3 (13.3)(28.7)
Gain on debt retirement6.9 — 6.9 100.0 
Interest expense, net35.7 33.0 2.7 8.2 
Income tax expense8.1 7.6 0.5 6.6 
Income from unconsolidated affiliates, net(0.5)(2.1)1.6 76.2 
Net loss attributable to noncontrolling interests— (0.2)0.2 100.0 
Net (loss) income attributable to Pyxus International, Inc.*$(3.2)$8.1 (11.3)(139.5)
Leaf:
Product revenues$515.8 $585.8 (70.0)(11.9)
Tobacco costs428.9 484.7 (55.8)(11.5)
Transportation, storage, and other period costs18.0 22.2 (4.2)(18.9)
Total product cost of goods sold446.9 506.9 (60.0)(11.8)
Product revenue gross profit68.9 78.9 (10.0)(12.7)
Product revenue gross profit as a percent of sales13.4 %13.5 %
Kilos sold86.0 111.7 (25.7)(23.0)
Average price per kilo$6.00 $5.24 0.76 14.5 
Average cost per kilo5.20 4.54 0.66 14.5 
Average gross profit per kilo0.80 0.70 0.10 14.3 
Processing and other revenues$48.3 $37.3 11.0 29.5 
Processing and other revenues costs of services sold40.1 27.2 12.9 47.4 
Processing and other gross profit8.2 10.1 (1.9)(18.8)
Processing and other gross profit as a percent of sales17.0 %27.1 %
All Other:
Sales and other operating revenues$2.2 $1.2 1.0 83.3 
Cost of goods and services sold3.9 1.4 2.5 178.6 
Gross loss(1.7)(0.3)(1.4)(466.7)
Gross loss as a percent of sales(77.3)%(25.0)%
* Amounts may not equal column totals due to rounding.

25


Sales and other operating revenues were $624.3 million for the three months ended September 30, 2023 and $566.3 million for the three months ended September 30, 2024, a decrease of $58.0 million, or 9.3%. This was due to a 23.0% decrease in kilo volumes sold primarily due to the accelerated timing of shipments from North America in the three months ended June 30, 2024 and delayed shipments from Africa in the three months ended September 30, 2024 compared to the prior-year period, partially offset by a 14.5% increase in average sales prices over this period, driven by higher tobacco prices.

Cost of goods and services sold were $535.5 million for the three months ended September 30, 2023 and $490.9 million for the three months ended September 30, 2024, a decrease of $44.6 million, or 8.3%. This was mainly due to the decrease in kilo volumes sold, partially offset by a 14.5% increase in average cost per kilo primarily due to undersupply conditions and inflation.

Gross profit as a percent of sales decreased from 14.2% for the three months ended September 30, 2023 to 13.3% for the three months ended September 30, 2024, due mainly to product and regional mix. Average gross profit per kilo increased 14.3%, primarily due to more favorable customer mix.

Gain on debt retirement of $6.9 million for the three months ended September 30, 2024 was due to the repurchase of $34.2 million aggregate principal amount of the 2027 Notes for $26.3 million, a 23.0% discount to par, during the current quarter. See "Note 11. Debt Arrangements" to the "Notes to Condensed Consolidated Financial Statements" for additional information.

Interest expense was $33.0 million for three months ended September 30, 2023 and $35.7 million for the three months ended September 30, 2024, an increase of $2.7 million, or 8.2%. This increase was driven by higher borrowings on our foreign seasonal lines of credit that were primarily used to purchase more expensive green tobacco, particularly from Africa, and increased variable interest rates. This increase was partially offset by partial repurchases of the 2027 Notes in March, April, and August 2024, as well as the partial repurchase of the Pyxus Term Loans in May 2024.
26


Six Months Ended September 30, 2024 and 2023
Six Months Ended September 30,
Change
(in millions, except per kilo amounts)20242023$%
Consolidated:
Sales and other operating revenues$1,201.2 $1,101.4 99.8 9.1 
Cost of goods and services sold1,041.9 939.5 102.4 10.9 
Gross profit159.3 161.8 (2.5)(1.5)
Gross profit as a percent of sales13.3 %14.7 %
Selling, general, and administrative expenses79.5 74.1 5.4 7.3 
Other expense, net5.9 3.7 2.2 59.5 
Restructuring and asset impairment charges0.3 1.3 (1.0)(76.9)
Operating income*73.5 82.7 (9.2)(11.1)
Gain on debt retirement8.2 — 8.2 100.0 
Interest expense, net69.0 63.8 5.2 8.2 
Income tax expense14.2 10.2 4.0 39.2 
(Income) loss from unconsolidated affiliates, net(3.1)0.1 (3.2)(3,200.0)
Net income (loss) attributable to noncontrolling interests0.3 (0.2)0.5 250.0 
Net income attributable to Pyxus International, Inc.*$1.4 $8.9 (7.5)(84.3)
Leaf:
Product revenue$1,105.0 $1,036.8 68.2 6.6 
Tobacco costs912.9 847.7 65.2 7.7 
Transportation, storage, and other period costs42.8 42.8 — — 
Total cost of goods sold955.7 890.5 65.2 7.3 
Product revenue gross profit149.3 146.2 3.1 2.1 
Product revenue gross profit as a percent of sales13.5 %14.1 %
Kilos sold181.7 197.2 (15.5)(7.9)
Average price per kilo$6.08 $5.26 0.82 15.6 
Average cost per kilo5.26 4.52 0.74 16.4 
Average gross profit per kilo0.82 0.74 0.08 10.8 
Processing and other revenues$90.1 $62.8 27.3 43.5 
Processing and other revenues costs of services sold77.5 47.2 30.3 64.2 
Processing and other gross profit12.6 15.6 (3.0)(19.2)
Processing and other gross profit as a percent of sales14.0 %24.8 %
All Other:
Sales and other operating revenues$6.1 $1.8 4.3 238.9 
Cost of goods and services sold8.7 1.8 6.9 383.3 
Gross loss(2.6)— (2.6)(100.0)
Gross loss as a percent of sales(42.6)%— %
* Amounts may not equal column totals due to rounding.

27


Sales and other operating revenues were $1,101.4 million for the six months ended September 30, 2023 and $1,201.2 million for the six months ended September 30, 2024, an increase of $99.8 million, or 9.1%. This was due to a 15.6% increase in average sales prices over this period, driven by higher tobacco prices, partially offset by 7.9% decrease in kilo volumes sold.

Cost of goods and services sold were $939.5 million for the six months ended September 30, 2023 and $1,041.9 million for the six months ended September 30, 2024, an increase of $102.4 million, or 10.9%. This was mainly due to a 16.4% increase in average cost per kilo, primarily due to undersupply conditions and inflation, partially offset by the decrease in kilo volumes sold.

Gross profit as a percent of sales decreased from 14.7% for the six months ended September 30, 2023 to 13.3% for the six months ended September 30, 2024, due mainly to regional mix. Average gross profit per kilo increased 10.8%, primarily due to a more favorable customer mix.

Selling, general, and administrative expenses were $74.1 million for the six months ended September 30, 2023 and $79.5 million for the six months ended September 30, 2024, an increase of $5.4 million, or 7.3%. This increase was primarily due to the recognition of $3.6 million for equity-based compensation pursuant to the Amended and Restated 2020 Incentive Plan, and a higher accrual for bonus compensation. See "Note 17. Equity-Based Compensation" to the "Notes to Condensed Consolidated Financial Statements" for additional information.

Gain on debt retirement of $8.2 million for the six months ended September 30, 2024 was due to the repurchase of $10.3 million of aggregate principal amount of the Pyxus Term Loans for $9.4 million, a 12.0% discount to par, and the repurchase of $34.2 million aggregate principal amount of the 2027 Notes for $26.3 million, a 23.0% discount to par. See "Note 11. Debt Arrangements" to the "Notes to Condensed Consolidated Financial Statements" for additional information.

Interest expense, net was $63.8 million for the six months ended September 30, 2023 and $69.0 million for the six months ended September 30, 2024, an increase of $5.2 million, or 8.2%. This increase was due to higher borrowings on our foreign seasonal lines of credit that were primarily used to purchase more expensive green tobacco, particularly from South America and Africa, and increased variable interest rates. This increase was partially offset by partial repurchases of the 2027 Notes in March, April, and August 2024, as well as the partial repurchase of the Pyxus Term Loans in May 2024.

Income tax expense was $10.2 million for the six months ended September 30, 2023 and $14.2 million for the six months ended September 30, 2024, an increase of $4.0 million, or 39.2%. This increase was primarily due to tax benefits in the prior period from foreign currency losses and foreign unremitted earnings, partially offset by improvements in the current period valuation allowances and uncertain tax benefits.

28


Liquidity and Capital Resources

Overview
Our primary sources of liquidity are cash generated from operations, short-term borrowings under our foreign seasonal lines of credit, availability under our ABL Credit Facility, and cash collections from our securitized receivables. Our liquidity requirements are affected by various factors from our core tobacco leaf business, including crop seasonality, foreign currency and interest rates, green tobacco prices, customer mix, crop size, and quality. Our leaf tobacco business is seasonal, and purchasing, processing, and selling activities have several associated peaks where cash on-hand and outstanding indebtedness may vary significantly compared to year end. The first three quarters of our fiscal year generally represent the peak of our working capital requirements.

Although we believe that our sources of liquidity will be sufficient to fund our anticipated operating needs for the next twelve months, we anticipate periods during which our liquidity needs for operations will approach the levels of our anticipated available cash and permitted borrowings under our credit facilities. Unanticipated developments affecting our liquidity needs, including with respect to the foregoing factors, and sources of liquidity, including impacts affecting our cash flows from operations and the availability of capital resources (including an inability to renew or refinance seasonal lines of credit), may result in a deficiency in liquidity. To address a potential liquidity deficiency, we may undertake plans to minimize cash outflows, which could include exiting operations that do not generate positive cash flow.

Debt Financing
We continue to finance our business with a combination of short-term and long-term credit lines, the long-term debt securities, advances from customers, and cash from operations when available. See "Note 11. Debt Arrangements" to the "Notes to Condensed Consolidated Financial Statements" for a summary of our short-term and long-term debt.

We continuously monitor and, as available, adjust funding sources as needed to enhance and drive various business opportunities. From time to time we may take steps to reduce our debt or otherwise improve our financial position. Such actions could include prepayments, open market debt repurchases, negotiated repurchases, other redemptions or retirements of outstanding debt, and refinancing of debt. The amount of prepayments or the amount of debt that may be repurchased, refinanced, or otherwise retired, if any, will depend on market conditions, trading levels of our debt, our cash position, compliance with debt covenants, and other considerations.

The following summarizes our total borrowing capacity at September 30, 2024 and 2023 under our short-term and long-term credit lines and letter of credit facilities and the remaining available amount after the reduction for outstanding borrowings and amounts reserved for outstanding letters of credit:

September 30, 2024September 30, 2023
(in millions)Total Borrowing CapacityRemaining Amount AvailableTotal Borrowing CapacityRemaining Amount Available
Senior Secured Credit Facilities:
ABL Credit Facility$120.0 $85.0 $100.0 $100.0 
Foreign seasonal lines of credit885.2 175.4 652.8 130.2 
Other long-term debt0.4 0.3 0.6 0.2 
Letters of credit10.8 3.0 10.5 3.7 
Total$1,016.4 $263.7 $763.9 $234.1 

The total borrowing capacity under the ABL Credit Facility increased $20.0 million when compared to the prior period as a result of the Company entering into the Third Amendment to the ABL Credit Agreement on October 24, 2023, which among other things, increased the aggregate amount of revolving loan commitments from $100.0 million to $120.0 million. The amounts presented as available under the ABL Credit Facility are subject to further limitations from the borrowing base consisting of certain eligible accounts receivable and inventory, reduced by specified reserves.

The total borrowing capacity of our foreign seasonal lines of credit increased $232.4 million when compared to the prior year and were primarily utilized to purchase green tobacco at higher prices. The amounts presented as available for certain of the foreign seasonal lines of credit are subject to further limitations by receivables and inventories as collateral and restrictive covenants.

29


Net Debt
We refer to "Net debt," a non-GAAP measure, as total debt liabilities less cash and cash equivalents. We believe this non-GAAP financial measure is useful to monitor leverage and to evaluate changes to the Company's capital structure. A limitation associated with using net debt is that it subtracts cash and cash equivalents, and therefore, may imply that management intends to use cash and cash equivalents to reduce outstanding debt and that cash held in certain jurisdictions can be applied to repay obligations owing in other jurisdictions and without reduction for applicable taxes. In addition, net debt suggests that our debt obligations are less than the most comparable GAAP measure indicates. The following summarizes the computation of net debt:

(in millions)September 30, 2024September 30, 2023March 31, 2024
Notes payable$744.8 $570.0 $499.3 
Current portion of long-term debt0.1 20.2 20.3 
Long-term debt (1)
489.5 574.0 497.7 
Total debt liabilities*$1,234.3 $1,164.2 $1,017.3 
Less: Cash and cash equivalents123.5 112.1 92.6 
Net debt*$1,110.9 $1,052.1 $924.7 
* Amounts may not equal column totals due to rounding
(1) Fluctuations in long-term debt include borrowings and repayments on the outstanding indebtedness under the ABL Credit Facility, along with repurchases of certain long-term debt. Weighted average borrowings outstanding under the ABL Credit Facility were $37.3 million and $50.6 million for the three and six months ended September 30, 2024, respectively.
Net debt increased as of September 30, 2024 when compared to September 30, 2023 from higher borrowings on our foreign seasonal lines of credit that were primarily used to purchase more expensive green tobacco, particularly from South America and Africa.

Working Capital

The following summarizes our working capital:

(in millions except for current ratio)September 30, 2024September 30, 2023March 31, 2024
Cash, cash equivalents, and restricted cash$130.9 $117.7 $99.8 
Trade and other receivables, net237.5 261.3 187.5 
Inventories and advances to tobacco suppliers, net1,052.6 944.8 952.1 
Recoverable income taxes3.0 5.1 4.5 
Prepaid expenses and other current assets62.1 52.0 66.4 
Total current assets*$1,486.1 $1,380.9 $1,310.2 
Notes payable$744.8 $570.0 $499.3 
Accounts payable152.6 153.2 181.2 
Advances from customers75.8 46.1 90.7 
Accrued expenses and other current liabilities103.4 94.0 97.0 
Income taxes payable13.6 12.6 8.5 
Operating leases payable8.3 8.4 8.1 
Current portion of long-term debt0.1 20.2 20.3 
Total current liabilities*$1,098.5 $904.4 $905.2 
Current ratio 1.4 to 11.5 to 11.4 to 1
Working capital$387.6 $476.5 $405.0 
* Amounts may not equal column totals due to rounding

Working capital declined from September 30, 2023 to September 30, 2024 by $88.9 million, or 18.7%, due to higher borrowings on our foreign seasonal lines of credit that were primarily used to purchase more expensive green tobacco, particularly from South America and Africa, and increased variable interest rates.
30


Inventories
The following summarizes inventory committed to a customer and uncommitted inventory balances for processed tobacco:

(in millions)September 30, 2024September 30, 2023March 31, 2024
Committed$733.9 $622.1 $570.4 
Uncommitted16.7 24.7 14.9 
Total processed tobacco$750.6 $646.8 $585.3 

Total processed tobacco increased from September 30, 2023 to September 30, 2024 by $103.8 million, or 16.0%, due to the higher costs of procuring and processing tobacco, along with delayed shipments out of Africa. Uncommitted levels of processed tobacco remain low as undersupply conditions persist in the global tobacco market. Challenging weather events in multiple geographies and shipping constraints, such as container availability and longer transit routes, have contributed to the continued undersupply conditions. See "Note 7. Inventories, Net" to the "Notes to Condensed Consolidated Financial Statements" for additional information.

Sources and Uses of Cash
We typically finance our non-U.S. tobacco operations with uncommitted short-term foreign seasonal lines of credit, normally extending for a term of 180 to 365 days, corresponding to the tobacco crop cycle in that market. These short-term foreign seasonal lines of credit are typically uncommitted and provide lenders the right to cease making loans and demand repayment of loans. These short-term foreign seasonal lines of credit are generally renewed at the outset of each tobacco season. We maintain various other financing arrangements to meet the cash requirements of our businesses. See "Note 11. Debt Arrangements" to the "Notes to Condensed Consolidated Financial Statements" for additional information.

We utilize capital in excess of cash flow from operations to finance accounts receivable, inventory, and advances to tobacco suppliers in foreign countries. In addition, we may periodically elect to purchase, redeem, repay, retire, or cancel indebtedness prior to stated maturity under our various foreign credit lines.

As of September 30, 2024, our cash, cash equivalents, and restricted cash was $130.9 million, of which approximately $76.5 million was held in non-U.S. jurisdictions for non-U.S. working capital needs, a majority of which is subject to exchange controls and certain of which is subject to tax consequences, which could limit our ability to fully repatriate these funds. Fluctuation of the U.S. dollar versus many of the currencies in which we have costs may have an impact on our working capital requirements. We will continue to monitor and hedge foreign currency costs, as needed.

31


The following summarizes the sources and uses of our cash flows:
Six Months Ended
September 30,
(in millions)20242023
Net income$1.7 $8.7 
Trade and other receivables(150.6)(143.2)
Inventories and advances to tobacco suppliers(100.7)(128.6)
Payables and accrued expenses(20.3)(10.3)
Advances from customers(14.1)3.6 
Other3.7 14.4 
Net cash used in operating activities$(280.3)$(255.4)
Collections from beneficial interests in securitized trade receivables 101.6 79.3 
Other(8.1)(6.2)
Net cash provided by investing activities$93.5 $73.1 
Net proceeds from short-term borrowings244.2 192.2 
Repayment of long-term borrowings(55.8)— 
Net proceeds (repayment) of revolving loan facilities35.0 (25.0)
Other(3.4)(3.9)
Net cash provided by financing activities$220.0 $163.3 
Effect of exchange rate changes on cash(2.1)(2.2)
Increase (decrease) in cash, cash equivalents, and restricted cash$31.1 $(21.2)

The change in cash, cash equivalents, and restricted cash for the six months ended September 30, 2024 compared to the six months ended September 30, 2023 increased by $52.3 million. This increase was mainly driven by higher borrowings on our foreign seasonal lines of credit that were primarily used to purchase more expensive green tobacco, particularly from South America and Africa, and the ABL Credit Facility, partially offset by the repayment of long-term debt.

Planned Capital Expenditures
Capital investments in our leaf operations were primarily for routine replacement of machinery and equipment, as well as investments in assets that will add value for our customers and increase our efficiency. We incurred approximately $9.8 million in capital expenditures for the six months ended September 30, 2024, and are expecting to incur an additional $20.5 million for the remainder of the fiscal year ending March 31, 2025, which includes expenditures expected to be funded through government assistance.

Pension and Postretirement Health and Life Insurance Benefits
The following summarizes cash contributions to pension and postretirement health and life insurance benefits:

Six Months Ended
September 30,
(in millions)2024
Contributions made during the period$2.3 
Contributions expected for the remainder of the fiscal year2.6 
Total$4.9 

Critical Accounting Policies and Estimates

As of the date of this report, there are no material changes to the critical accounting policies and estimates previously disclosed in Part II, Item 7 "Management's Discussion and Analysis of Financial Condition and Results of Operations" in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024.

32


Item 3. Quantitative and Qualitative Disclosures About Market Risk

There have been no significant changes to our market risk exposures since March 31, 2024. For a discussion of our exposure to market risk, see Part II, Item 7A "Quantitative and Qualitative Disclosures About Market Risk" contained in our Annual Report on Form 10-K for the fiscal year ended March 31, 2024.

Item 4. Controls and Procedures

Evaluation of Disclosure Controls and Procedures
We maintain disclosure controls and procedures (as defined in Rule 13a-15(e) of the Securities Exchange Act of 1934, as amended (the "Exchange Act")) designed to provide reasonable assurance that the information required to be disclosed in the reports we file or submit under the Exchange Act is recorded, processed, summarized, and reported within the time periods specified in the Securities and Exchange Commission’s rules and forms and that this information is accumulated and communicated to our management, including our Chief Executive Officer and Chief Financial Officer, as appropriate, to allow for timely decisions regarding required disclosure. Due to inherent limitations, our disclosure controls and procedures, however well designed and operated, can provide only reasonable assurance (not absolute) that the objectives of the disclosure controls and procedures are met.

Our management, with the participation of our Chief Executive Officer and Chief Financial Officer, evaluated the effectiveness of the design and operation of our disclosure controls and procedures (as required by Rule 13a-15(b) of the Exchange Act), as of September 30, 2024. Based on this evaluation, our Chief Executive Officer and Chief Financial Officer concluded our disclosure controls and procedures (as defined in Rule 13a-15(e) of the Exchange Act) were effective to provide reasonable assurance as of September 30, 2024.

Changes in Internal Control over Financial Reporting
As required by Rule 13a-15(d) under the Exchange Act, our management, including our Chief Executive Officer and Chief Financial Officer, have evaluated our internal control over financial reporting to determine whether any changes occurred during the quarter covered by this quarterly report that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

There were no changes that occurred during the three months ended September 30, 2024 that have materially affected, or are reasonably likely to materially affect, our internal control over financial reporting.

Part II. Other Information

Item 1. Legal Proceedings

See "Note 16. Contingencies and Other Information" to the "Notes to Condensed Consolidated Financial Statements" for additional information with respect to legal proceedings, which are incorporated by reference herein.

Item 1A. Risk Factors

In addition to the other information set forth in this report and in our other filings with the Securities and Exchange Commission, investors should carefully consider our risk factors, which could materially affect our business, financial condition, or operating results. As of the date of this report, there are no material changes or updates to the risk factors previously disclosed in Part I, Item 1A "Risk Factors" in the Company's Annual Report on Form 10-K for the fiscal year ended March 31, 2024.

33


Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Issuer Purchases of Equity Securities

During the three months ended September 30, 2024, the Company repurchased the following shares of its common stock:

Total Number of Shares Purchased
Average Price Paid per Share 1
Total Number of Shares Purchased as Part of Publicly Announced Plans or Programs
Approximate Dollar Value of Shares that May Yet Be Purchased Under the Plans or Programs 2
July 1, 2024 - July 31, 2024— $— — $— 
August 1, 2024 - August 31, 2024392,156 2.55 — — 
September 1, 2024 - September 30, 2024— — — — 
Total392,156 $2.55 — — 
1 Price paid per share includes broker commission fees of $0.05 per share.
2 On August 15, 2024, the Board of Directors authorized a program to repurchase up to $10,000,000 plus fees and expenses of our common stock in the open market or through privately negotiated transactions, subject to limitations under the Company's debt agreements (which currently limit the aggregate amount that may be applied to repurchase shares of common stock to $1,000,000). This program expires on August 15, 2027. The number, price, structure and timing of share repurchases will be at the Company's sole discretion, and future repurchases of our common stock are dependent on market conditions, liquidity needs, and certain restrictions under our debt arrangements, among other factors.

No cash dividends on shares of common stock of Pyxus International, Inc. were paid to shareholders during the six months ended September 30, 2024. As of September 30, 2024, the payment of such dividends is restricted under the terms of our debt agreements.

Item 5. Other Information

During the three months ended September 30, 2024, none of the Company's directors or officers (as defined in Rule 16a-1(f) of the Exchange Act) adopted or terminated a "Rule 10b5-1 trading arrangement" or adopted or terminated a "non-Rule 10b5-1 trading arrangement" (as such terms are defined in Item 408 of Regulation S-K).

Item 6. Exhibits

Certification of Chief Executive Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
Certification of Chief Financial Officer pursuant to Section 302 of the Sarbanes-Oxley Act of 2002 (filed herewith)
Certification of Chief Executive Officer and Chief Financial Officer pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 (filed herewith)
101.INS
XBRL Instance Document - the instance document does not appear in the Interactive Data File because its XBRL tags are embedded within the Inline XBRL document (filed herewith)
101.SCH
Inline XBRL Taxonomy Extension Schema (filed herewith)
101.CAL
Inline XBRL Taxonomy Extension Calculation Linkbase (filed herewith)
101.DEF
Inline XBRL Taxonomy Extension Definition Linkbase (filed herewith)
101.LAB
Inline XBRL Taxonomy Extension Label Linkbase (filed herewith)
101.PRE
Inline XBRL Taxonomy Extension Presentation Linkbase (filed herewith)
104
Cover Page Interactive Data File (formatted as Inline XBRL and contained in Exhibit 101)

34


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.
Pyxus International, Inc.
Date: November 12, 2024
/s/ Philip C. Garofolo
Philip C. Garofolo
Senior Vice President Finance and Chief Accounting Officer
(Principal Accounting Officer)
                
35